Study Product Guidelines and Considerations  3 of 54 Version 6 
  13Sept2022  Full Protocol Title  
Prebiotic Treatment in People with Schizophrenia  
 
 
Principal Investigator:  
Robert W. Buchanan, M.D.  
Director  
Maryland Psychiatric Research Center  
  
Supported by:  
The National Center for Complementary and Integrative Health 
1 R61 AT009990 -01 
 
Study Intervention Provided by:  
Jackson GI Medical 
 
Study Product Guidelines and Considerations  4 of 54 Version 5 
  26Jan2021  Tool Revision History  
Version Number:  1.1 
Version Date: 2/5/2019  
Summary of Revisions Made: See attached “Summary of Review Responses” document.  
Version Number:  1.2 
Version Date:  3/26/2019  
Summary of Revisions Made:  See attached “Summary of Review Responses” document.  
Version Number:  1.3 
Version Date:  4/8/2019  
Summary of Revisions Made: See attached “Summary of Review Responses” document.  
Version Number:  1.4 
Version Date:  6/13/2019  
Summary of Revisions Made:  See attached “Summary of Review Responses” document.  
 
Version Number: 2.1  
Version Date: 8 /13/2019  
Summary of Revisions Made: Per OHRP requirement, the “Potential Benefits” section of the consent 
document was revised to include a more detailed list of potential benefits to the participant.  
 
Version Number 2.2  
Version Date: 12/ 16/19  
Summary of Revisions Made: Revised the BMI inclusion criterion to less than or equal to 40. Study medication name was changed from FOS to OEI due to manufacturer request;  actual  composition of 
the study medication was not changed.  
 
Version Number 2.3  
Version Date: 1/23/2020  
Summary of Revisions Made: Samantha Trikeriotis , Joel Palachuvattil, and Sharon Pugh were added 
as study team member s.   
 
Version Number 2.4  
Version Date: 7/16/2020  
Summary of Revisions Made: Hanna Michel  and Franklin Blatt  were  added,  and Megan Powell  
removed from the study team roster .   
 
Version 3  
Version Date: 8/12/20  
Summary of Revisions Made: Gopal Vyas was added,  and Anne Werk heiser removed , from the study 
team roster. The PIS and PPSS acronyms on the Schedule of Evaluations  were expanded to clarify 
the assessment names.
Protocol Template, Version 6 5 of 54 Version 4  
Version Date: 9/17/20  
Summary of Revisions Made: Heidi Wehring was  removed from the study team roster ; the Protocol 
Participation Status Sheet was removed from Days 1- 9 on the Schedule of Evaluations; the adverse 
event section was revised to correct the inconsistencies in how we track and capture adverse events  
on the side effect checklist .   
 
Version 5  
Version Date: 1/ 26/21  
Summary of Revisions Made: Administrative change - Clarif ication of  the intent of  the exclusion of 
antibiotics for acute use and current infections and not medications for longer term use with 
antibiotic properties.   
 
Version 6  
Version Date: 9/13/2022 
Summary of Revisions Made: Administrative changes – Revisions to the study team roster: Added 
Colin Frazier; Removed Hanna Michel, Samantha Trikeriotis, and Samuel Kane- Gerard.   
Protocol Template, Version 6  6 of 54 TABLE OF CONTENTS  
                                                                    Page  
Clinical Intervention Study Protocol Template  ............................................................................ 1 
PREFACE  ............................................................................................................................................... 2 
Full Protocol Title  ................................................................................................................................. 3 
Jackson GI Medical  .................................................................................................................. 3 
Tool Revision History ................................................................................................................ 4 
TABLE OF CONTENTS  ....................................................................................................................... 5 
STUDY TEAM ROSTE R ........................................................................................................ 11 
PARTICIPATING STUDY SITES  ......................................................................................... 11 
1. STUDY OBJECTIVES  .................................................................................................................... 15 
1.1 Primary Objective  ......................................................................................................... 15 
1.2 Secondary Objectives  ................................................................................................. 15 
2. BACKGROUND AND RATIONALE  ............................................................................................ 15 
2.1 Background on Condition, Disease, or Other Primary Study Focus  .................... 15 
People with schizophrenia have a broad range of neurocognitive impairments, including 
abnormalities in attention, executive function, verbal and visual learning and 
memory, working memory, pro cessing speed, and social cognition (Nuechterlein et 
al, 2004). These impairments are major determinants of functional outcome in schizophrenia (Green, 1996; Green et al, 2004). Unfortunately, first and second generation antipsychotics have limited benefit s for these impairments (Keefe et al, 
2007; Buchanan et al, 2007), which has led to the evaluation of add -on 
pharmacological agents for the treatment of cognitive impairments, but results, to date, have been largely disappointing (Choi et al, 2013; Buchana n et al, 2007; 
Freedman et al, 2008; Winterer et al, 2008; Lieberman et al, 2013; Umbricht  et al, 2014). Cognitive remediation and other non- pharmacological strategies have shown 
some promise, but the observed beneficial effects rarely generalize beyond t he 
measures included in the training exercises (Dixon et al, 2010). In the absence of an effective treatment, cognitive impairments remain a critical unmet therapeutic need, and the development of a novel approach for the treatment of these impairments remains a central therapeutic challenge.  ................................................................. 15
 
2.2 Study Rationale  ............................................................................................................ 16 
Over the past 10 years, considerable evidence has emerged from animal studies to 
suggest that the gut microbiome has significant effects on brain development and behavior, with bidirectional communication between the enteric nervous system, gut and the central nervous system (CNS) (Diaz Heijtz et al, 2011; Douglas -Escobar et 
Protocol Template, Version 6  7 of 54 al, 2013; Dinan et al, 2014). The gut microbiota have been shown to: a) produce 
multiple neurotransmitters, including gamma- aminobutyric acid (GABA), dopamine, 
norepinepherine, and serotonin, and may regulate CNS levels of these neurotransmitters; b) modulate brain development through the regulation of synaptogenesis; and c) modulate the level s of stress hormones during brain 
development, which may affect stress response and anxiety behavior (Diaz Heijtz et al, 2011; Dinan et al, 2014; Sudo et al, 2004; O’Mahony et al, 2015). Moreover, the gut microbiota effects the production of neurotrophins,  including brain- derived 
neurotrophic factor (BDNF), which plays a significant role in neurogenesis and synaptic plasticity (Sudo et al, 2004; Nemani et al, 2015).  ................................... 16
 
3. STUDY DESIGN  .............................................................................................................................. 17 
4. SELECTION AND ENROLLMENT OF PARTICIPANTS  ......................................................... 17 
4.1 Inclusion Criteria ........................................................................................................... 18 
4.2 Exclusion Criteria  ......................................................................................................... 18 
4.3 Study Enrollment Procedures  .................................................................................... 18 
5. STUDY INTERVENTIONS  ............................................................................................................. 20 
5.1 Interventions, Administration, and Duration  ............................................................. 20 
5.2 Handling of Study Interventions  ................................................................................. 20 
5.3 Concomitant Interventions  .......................................................................................... 20 
5.3.1  Allowed Interventions  ........................................................................................................ 20 
5.3.2  Required Interventions  ........................................................................................................ 21 
5.3.3  Prohibited Interventions  ...................................................................................................... 21 
5.4 Adherence Assessment  .............................................................................................. 21 
6. STUDY PROCEDURES  ................................................................................................................. 21 
6.1 Schedule of Evaluations  ............................................................................................. 21 
6.2 Description of Evaluations  .......................................................................................... 23 
6.2.1  Screening Evaluation  .......................................................................................................... 24 
6.2.2  Enrollment, Baseline, and/or Randomization ..................................................................... 26 
The study biostatistician will use a permuted block randomization system (block sizes 2 or 4), in which treatment assignment order is random within each block, with an equal number of participants assigned to each treatment, to generate a l ist of treatment assignments. Thus, it will be 
difficult to ascertain the next treatment assignment, even if a participant becomes unblinded, while any imbalance in the number of participants between the treatment groups will be kept within tight limits.  ........................................................................................................................... 27
 
6.2.3  Blinding  .............................................................................................................................. 27 
6.2.4  Double -Blind Treatment Phase  ........................................................................................... 28 
6.2.5  Completion/Final Evaluation  .............................................................................................. 28 
7. SAFETY ASSESSMENTS  ............................................................................................................. 29 
Protocol Template, Version 6  8 of 54 7.1 Specification of Safety Parameters  ........................................................................... 29 
7.2 Methods and Timing for Assessing, Recording, and Analyzi ng Safety Parameters
 ........................................................................................................................................ 29 
OEI is considered a food supplement and is being used for its indication to improve gut 
bacteria composition, thus it is not a drug product nor is it being used for any other 
indication. Participants randomized to OEI will receive 4 grams of OEI, mixed in water, three times a day for 10 days. We chose the 12 grams/day dose, because a previous study suggests that  this dose is well tolerated and based on data from a 
pilot study conducted by our co- investigators.  ........................................................ 29
 
Participants randomized to placebo will receive maltodextrin (4 grams), mixed in water, 
three times a day for 10 days. Maltodextrin is a polysaccharide composed of glucose units, a mixture of chains that vary from 3 to 17 glucose units long; and is freely soluble or readily dispersible in water and is a quickly digested carbohydrate. Maltodextrin has previously been used in studies evaluating the effect of OEI prebiotics (Abrams et al, 2005; Casellas et al, 2007; Roller et al, 2007; De Peter et al, 2008; Dehghan et al, 2014), and produces minimal changes in inflammatory and metabolic measures (Casellas et al, 2007; Dehghan et al, 2014).  ...................... 30
 
7.3 Adverse Events and Serious Adverse Events  ......................................................... 30 
7.4 Reporting Procedures  ................................................................................................. 31 
7.5 Follow- up for Adverse Events  .................................................................................... 32 
7.6 Safety Monitoring  ......................................................................................................... 32 
8. INTERVENTION DISCONTINUATION  ........................................................................................ 33 
9. STATISTICAL CONSIDERATIONS  ............................................................................................. 33 
9.1 General Design Issues  ................................................................................................ 33 
9.2 Sample Size and Randomization  .............................................................................. 33 
Sample Size .................................................................................................................................... 33 
The proposed sample si ze is 20; the participants will be of either sex and any race, and between 
18-60 years old. They will meet Diagnostic and Statistical Manual of Mental Disorders (DSM) -5 
criteria for schizophrenia or schizophreniform or schizoaffective disorder.  .................................. 33 
Treatment Assignment Procedures  ................................................................................................. 34 
9.3  Definition of Populations  ............................................................................................. 34 
9.4 Interim Analyses and Stopping Rules  ....................................................................... 34 
9.5 Outcomes  ...................................................................................................................... 34 
9.5.1  Primary Outcome  ................................................................................................................ 34 
9.6 Data Analyses ............................................................................................................... 35 
10. DATA COLLECTION AND QUALITY ASSURANCE  ............................................................. 36 
10.1  Data Collection Forms  ................................................................................................. 36 
Protocol Template, Version 6  9 of 54 10.2  Data Management  ....................................................................................................... 36 
10.3  Quality Assurance  ........................................................................................................ 36 
10.3.1  Training ........................................................................................................................... 36 
10.3.2  Quality Control Committee  ............................................................................................ 36 
10.3.3  Metrics  ............................................................................................................................ 37 
We will strive to ensure that all participants receive ≥ 90% of their assigned medication. The 90% 
criterion incre ases the likelihood that participants will receive adequate treatment to evaluate the 
effect of OEI on the biological signature. In order to monitor adherence, participants will be observed by research staff while they ingest the study medication. Since al l participants will be 
inpatients, we do not expect problems with adherence, but we will carefully monitor adherence patterns, which will be described within each treatment group as part of any presentation of study results.  ............................................................................................................................................. 37
 
10.3.4  Protocol Deviations  ........................................................................................................ 37 
10.3.5  Monitoring ...................................................................................................................... 37 
11. PARTICIPANT RIGHTS AND CONFIDENTIALITY  ................................................................ 37 
11.1  Institutional Review Board (IRB) Review  ................................................................. 37 
11.2  Informed Consent Forms  ............................................................................................ 38 
11.3  Participant Confidentiality  ........................................................................................... 38 
11.4  Study Discontinuation  .................................................................................................. 38 
12. COMMITTEES  ............................................................................................................................... 38 
13. PUBLICATION OF RESEARCH FINDINGS  ............................................................................ 38 
14. REFERENCES  .............................................................................................................................. 38 
15. SUPPLEMENTS/APPENDICES ................................................................................................. 45 
WHAT ARE MY RESPONSIBILITIES IF I TAKE PART IN THIS RESEARCH?  .............. 48 
POTENTIAL RISKS/DISCOMFORTS: ............................................................................................ 48 
POTE NTIAL BENEFITS  .................................................................................................................... 48 
COSTS TO PARTICIPANTS  ............................................................................................................. 49 
PAYMENT TO PARTICIPANTS  ...................................................................................................... 50 
You will be paid by cash or check.  If paid by cash, then you will be paid at the end of each visit.  If paid by check, then it may take up to 4 -6 weeks to receive payment.  .......................................... 50
 
CONFIDENTIALITY AND ACCESS TO RECORDS  .................................................................... 50 
RIGHT TO WITHDRAW  ................................................................................................................... 50 
CAN I BE REMOVED FROM THE RESEARCH?  ................................................................. 51 
Protocol Template, Version 6  10 of 54 UNIVERSITY STATEMENT CONCERNING RESEARCH RISKS  ............................................ 51 
I. Procedures Schedule 
II. Informed Consent Form Template  
III. DSMB Roster  
Protocol Template, Version 6  11 of 54 STUDY TEAM ROSTER  
Robert W. Buchanan, M.D.  
55 Wade Avenue  
Catonsville, MD 21228  
410-402-7876 (p)  
410-402-7198 (f)  
rbuchanan@som.umaryland.edu  M Patricia Ball   
55 Wade Avenue  
Catonsville, MD 21228  
410-402-6844 (p)  
410-402-7198 (f)  
pball@som.umaryland.edu  
 Franklin Blatt  
55 Wade Avenue  
Catonsville, MD 21228  
410-402-7599 (p)  
410-402-7198 (f)  
fblatt@som.umaryland.edu  
 
Zeni Encomienda  
55 Wade Avenue  
Catonsville, MD 21228  
410-402-6844 (p)  
410-402-7198 (f)  
zencomienda@som.umaryland.
edu Colin Frazier  
55 Wade Avenue  
Catonsville, MD 21228  
410-402-6411 (p)  
410-402-7198 (f)  
cfrazier @som.umaryland.edu  
 Matthew Glassman  
55 Wade Avenue  
Catonsville, MD 21228  
410-402-6411 (p)  
410-402-7198 (f)  
mglassman@som.umaryland.edu  
 
David Gorelick, M.D.  
55 Wade Avenue  
Catonsville, MD 21228  
410-402-6806 (p)  
410-402-7198 (f)  
dgorelick@som.umaryland.edu  
 Ann Kearns  
55 Wade Avenue  
Catonsville, MD 21228  
410-402-6854 (p)  
410-402-7198 (f)  
akearns@som.umaryland.edu  
 Deanna L. Kelly, Pharm.D.  
55 Wade Avenue  
Catonsville, MD 21228  
410-402-6861 (p)  
410-402-7198 (f)  
dlkelly@som.umaryland.edu 
 
Joel Palachuvattil  
55 Wade Avenue  
Catonsville, MD 21228  
410-402-6839 (p)  
410-402-7198 (f)  
jpalachu@som.umaryland.edu  Sharon Pugh  
55 Wade Avenue  
Catonsville, MD 21228  
410-402-7113 (p)  
410-402-7198 (f)  
spugh@som.umaryland.edu  Gopal Vyas, D.O.  
55 Wade Avenue  
Catonsville, MD 21228  
410-402-6865 (p)  
410-402-7198 (f)  
gopalvyas@som.umaryland.edu  
 
Jennifer Zaranski  
55 Wade Avenue  
Catonsville, MD 21228  
410-402-6060 (p)  
410-402-7198 (f)  
jzaranski@som.umaryland.edu  
   
 
PARTICIPATING STUDY SITES  
Maryland Psychiatric Research Center site investigator s: 
Robert W. Buchanan, M.D.   
55 Wade Avenue  
Catonsville, MD 21228  
410-402-7876 (p)  
410-402-7198 (f)  
rbuchanan@som.umaryland.edu  
 
Deanna L. Kelly, Pharm.D., BCPP  
55 Wade Avenue  
Protocol Template, Version 6  12 of 54 Catonsville, MD 21228  
410-402-6861 (p)  
410-402-7198 (f)  
dlkelly@som.umaryland.edu 
 
 
PRÉCIS  
Study Title  
Prebiotic Treatment in People with Schizophrenia  
Objectives  
The primary objective of the study is to examine the effect of a 10- day course of 
the prebiotic: Prebiotin, an oligofructose- enriched inulin ( OEI), on serum butyrate 
levels. We hypothesize that OEI , compared to placebo, will produce a greater 
increase in s erum butyrate levels secondary to the stimulatory effects of OEI  on the 
activity of known butyrate- producing bacteria.  
 
Design and Outcomes   
We will conduct a 10- day, double- blind, placebo- controlled, randomized clinical trial 
to examine the effect of OE I on serum butyrate levels . There will be two study 
phases: 1) a 2- week Evaluation Phase, during which potential participants will 
undergo baseline medical, vital sign, and symptom assessments to determine whether they meet inclusion criteria; and 2) a 10- day Double- blind Treatment  
Phase.  
 Participants who complete the 2- week Evaluation Phase and continue to fulfill 
inclusion criteria will be entered into the 10- day double -blind treatment phase. 
Participants will be randomly assigned to OEI or placebo- OEI, with approximately 
10 par ticipants in each group . Participants randomized to OEI will receive 4 grams 
of OEI, mixed in water, three times a day for 10 days , for a total dose of 12 grams . 
Participants randomized to placebo- OEI will receive 4 grams of maltodextrin, mixed 
in water, t hree times a day for 10 days.  A non- blind pharmacist will dispense all 
study medications. The blind will be broken only if a medical emergency requires this information.  
 We will consent and evaluate up to 30 participants to reach the goal of approximately 24 participants randomized and 20 study completers .  We will plan 
to randomize approximately 24 participants, because we anticipate a 10- 20% 
attrition rate.  We will consent and evaluate up to 30 participants, because we anticipate that some participant s, who provide informed consent, may not meet 
eligibility criteria. However, we do not expect to need to consent 30 participants, because potential participants will be prescreened, through our partial HIPPA waiver, and those with obvious exclusion criteri a (e.g. do not meet the age range 
criterion) will not undergo the informed consent process.  
 
Protocol Template, Version 6 13 of 54 If a participant is unable to tolerate the study medication, then they will be 
withdrawn from study treatment, but we will continue to make every effort to collect  
scheduled study assessments.  
 All participants will receive the identical, standardized diet, provided by a registered dietician, which will consist of 3 meals and one snack. The daily diet breakdown is approximately 2700 calories with the following composition: 100 g protein, 400 g carbohydrates, 28 g fiber, 6.7% saturated fat, 28% total fat, 240 mg cholesterol and 4.4 g sodium.  
 
Interventions and Duration  
We are using a prebiotic, natural product: Orafti® Synergy1, sold in the US under the brand name Prebiotin®, for the study. Prebiotin® is an oligofructose- enriched 
inulin ( OEI). Prebiotin®  will be provided by Jackson GI Medical. Prebiotin®  is 
considered a food powder, not a bacterial strain. Prebiotin® is a combination of chicory inulin fractions with selected chain lengths; the shorter chain inulin (oligofructose) is combined with longer chain inulin in essentially equal amounts. Inulins are indigestible polysaccharides and have been generally recognized as safe by the US Food and Drug Administration. Inulin consists of oligo- and 
polysaccharides composed of fructose units linked together by ß -(2, 1) -linkages. 
Almost every fructose chain is terminated by a glucose unit. The number of fructose and glucose units in inulin (Degree of Polymerization; DP) ranges between 2 and 60. Shorter chain inulin (oligofructose) consists of oligosaccharides obtained by partial enzymatic hydrolysis from inulin. Part of shorter chain inulin is terminated by a glucose unit. The degree of polymerization is less than 10. Longer  chain inulin 
consists of inulin of which shorter fractions were removed. Almost every molecule is terminated by a glucose unit and has a DP of 10 or higher.  
 Prebiotin® is a fine, white to slightly yellow powder, which is hygroscopic and slightly sweet. T he product is produced by Beneo- Orafti SA and distributed in the 
US by Jackson GI Medical.   Prebiotin® meets full GMP requirements of characterization and standardization and full requirements contained in the NCCIH policy for Natural Product Ingredients (see https://nccih.nih.gov/research/policies/naturalproduct.htm#ctconsiderations
).  
The product specification sheet includes the taxonomic nomenclature and the analysis of the product for contaminants/impurities, including microorganisms. This specification sheet also contains solubility information and minimum durability/stability information. Each parameter contains the limit, the units, the reference method and the frequency of continued testing. In addition, the information for nutritional declaration in the US by 21 CFR 101.9 is included in the specification sheet.    
 The total length of study participation for each individual participant will be 25 days. There will be 5 study visits: 2 visits during the 2- week Evaluation Phase and 3 visits 
during the Double- blind Treatment Phase.  
Protocol Template, Version 6  14 of 54  
The total time of study participation is 18- 20 hours. The two Evaluation Phase visits 
will take a combined total of 3- 5 hours to complete. The Day 0 and Day 11 visits 
will take approximately 7 hours each to complete; on these days participants will undergo the inulin ( OEI) challenge to assess the extent to which OEI has modified 
the biological signature: serum butyrate levels. The extended length of the visit is due to the need to wait 6 hours for the peak in serum butyrate following the inulin administration. The Day 10 visit will take approximately 1 hour to complete.  
 
Sample Size and Population  
Participants (n=20) will be of either sex and any race, and between 18- 60 years 
old. Participants will be recruited from the greater Baltimore metropolitan area. 
They will meet Diagnostic and Statistical Manual of Mental Disorders (DSM) -5 
(APA, 2013) criteria for schizophreni a or schizophreniform or schizoaffective 
disorder. A best estimate diagnostic approach will be utilized in which information from the Structured Clinical Interview for DSM -5 (First et al, 2015) is supplemented 
by information from family informants, previous psychiatrists, and medical records to generate a diagnosis. Participants will be judged by their primary clinician to be clinically stable and will be prescribed the same antipsychotic and dose for at least 14 days prior to study entry. In light of the potential impact of obesity on the gut 
microbiota (Brahe et al, 2013), participants will be required to have a body mass index (BMI) ≤ 40, i.e., we will restrict the population to those with normal or mild to 
moderate increased BMI and exclude potential par ticipants who are morbidly 
obese. The proposed BMI criterion reflects the typical range of BMI values of people with schizophrenia who enter our treatment units and studies, and will serve 
to minimize the impact of morbid obesity on the study results. We w ill not restrict 
the type of antipsychotic, with which the participant is treated.  
 Participants with inflammatory bowel diseases or other gastrointestinal disorders, whose pathology or treatment could significantly increase the risk associated with the pr oposed treatment; who have an organic brain disorder; who have an 
intellectual disability; who have been treated with an antibiotic or immune therapy within the last three months; who have been treated with a prebiotic or probiotic within the last three months; who are unable to understand English or cooperate 
with study procedures; or who meet DSM -5 criteria for alcohol or substance use 
disorders (except Tobacco Use Disorder) within the last 3 months will be excluded. Female participants who are pregnant or lactating will be excluded. Participants must be judged competent to participate in the informed consent process and provide voluntary informed consent.  
 The use of the proposed inclusion/exclusion criteria will result in a study population, 
which is rep resentative of hospitalized people with schizophrenia and related 
disorders; minimizes the effect of potential confounder variables; and maximizes 
the safety of the study protocol.  
 
Protocol Template, Version 6  15 of 54 The study biostatistician will use a permuted block randomization system ( block 
sizes 2 or 4), in which treatment assignment order is random within each block, 
with an equal number of participants assigned to each treatment, to generate a list of treatment assignments. Thus, it will be difficult to ascertain the next treatment assignment, even if a participant becomes unblinded, while any imbalance in the 
number of participants between the treatment groups will be kept within tight limits. All raters, investigators and other staff will be blind to treatment assignment except for the pharmacist. The pharmacist does not participate in assessing any of the 
primary symptom or side effect dependent variables and conveys no information about treatment assignment to participants or staff except in a medical emergency.  
1. STUDY OBJECTIVES  
1.1 Primary Objective  
In the context of a 10- day, double- blind, placebo- controlled, randomized clinical 
trial (RCT), we will examine whether the prebiotic: Prebiotin (12g/day), an oligofructose- enriched inulin ( OEI), increases serum butyrate levels. Parti cipants 
with schizophrenia or a related disorder will be randomly assigned to OEI  or 
placebo- OEI, with approximately 10 participants in each group . We hypothesize 
that OEI, compared to placebo, will produce a greater increase in serum butyrate 
levels secon dary to the stimulatory effects of OEI on known butyrate -producing 
bacteria.  
1.2 Secondary Objectives 
N/A 
2. BACKGROUND AND RATIONALE  
2.1 Background on Condition, Disease, or Other Primary Study Focus  
People with schizophrenia have a broad range of neurocognitive impairments, including abnormalities in attention, executive function, verbal and visual learning and memory, working memory, processing speed, and social cognition (Nuechterlein et al, 2004). These impairments are major determinants of func tional 
outcome in schizophrenia (Green, 1996; Green et al, 2004). Unfortunately, first and second generation antipsychotics have limited benefits for these impairments (Keefe et al, 2007; Buchanan et al, 2007), which has led to the evaluation of add-
on pharmacological agents for the treatment of cognitive impairments, but results, 
to date, have been largely disappointing (Choi et al, 2013; Buchanan et al, 2007; 
Freedman et al, 2008; Winterer et al, 2008; Lieberman et al, 2013; Umbricht  et al, 
2014). Cognit ive remediation and other non- pharmacological strategies have 
shown some promise, but the observed beneficial effects rarely generalize beyond the measures included in the training exercises (Dixon et al, 2010). In the absence of an effective treatment, co gnitive impairments remain a critical unmet therapeutic 
Protocol Template, Version 6  16 of 54 need, and the development of a novel approach for the treatment of these 
impairments remains a central therapeutic challenge.  
 2.2 Study Rationale  
Over the past 10 years, considerable evidence has emerged from animal studies to suggest that the gut microbiome has significant effects on brain development and behavior, with bidirectional communication between the enteric nervous system, gut and the cen tral nervous system (CNS) (Diaz Heijtz et al, 2011; Douglas -
Escobar et al, 2013; Dinan et al, 2014). The gut microbiota have been shown to: a) produce multiple neurotransmitters, including gamma- aminobutyric acid (GABA), 
dopamine, norepinepherine, and serotonin, and may regulate CNS levels of these neurotransmitters; b) modulate brain development through the regulation of 
synaptogenesis; and c) modulate the levels of stress hormones during brain 
development, which may affect stress response and anxiety behavior (Diaz Heijtz 
et al, 2011; Dinan et al, 2014; Sudo et al, 2004; O’Mahony et al, 2015). Moreover, the gut microbiota effects the production of neurotrophins, including brain- derived 
neurotrophic factor (BDNF), which plays a significant role in neurogenesis and synaptic plasticity (Sudo et al, 2004; Nemani et al,  2015).  
The gut microbiome may also affect brain development and function through its regulation of immune system function, which is mediated, in part, through the production of short -chain fatty acids (SCFA). There are three major SCFAs: 
butyrate, propionate, and acetate. Butyrate is of particular interest, since it plays a key role in maintaining gut homeostasis and epithelial integrity: butyrate is the primary energy source for intestinal colonocytes; and, of the three SCFAs, butyrate 
appears to have the most pronounced effects on immune system function and may exert its effects directly through immune pathways and indirectly through the maintenance of the integrity of the intestinal -blood barrier (Hamer et al, 2008; Louis 
et al, 2010; Brahe et al, 2013; Vital et al, 2014). The intestinal -blood barrier restricts 
the entrance of toxins, pathogens and antigens into the blood circulation; thus, increased permeability could lead to the entrance of substances and subsequent immune response.  
 The multiple effects of the gut microbiome on brain development and behavior, suggest that alterations in the gut microbiome may occur in schizophrenia and play a part in the pathophysiology of the disorder. The inc reased prevalence of 
gastrointestinal disorders in schizophrenia; the association of infections, including infections with Toxoplasma gondii, which can induce intestinal inflammation, with 
the risk for the development of schizophrenia; and evidence of incr eased gut 
permeability provide further indirect evidence for disruption of the gut microbiome 
in this disorder (Dinan et al, 2014; Nemani et al, 2015; Severance et al, 2012; Severance et al, 2014). Although a number of studies have been conducted in other neuropsychiatric disorders, including autism (Parracho et al, 2005; Tomova et 
al, 2015), which demonstrate altered bacterial composition of the gut microbiome, there is only one published study of the microbiome in schizophrenia. Yolken and colleagues exam ined the oropharyngeal microbiome in people with schizophrenia, 
Protocol Template, Version 6 17 of 54 and found that there were increased levels of the bacteriophage, Lactobacillus 
phage phiadh, genome in the schizophrenia group, which were correlated with co-occurring immunological disorders (Yolken et al, 2015). There is one published study of gut microbiota in schizophrenia. Shen and colleagues found a significant reduction in butyrate producers in people with schizophrenia compared to healthy controls (Shen et al. Schiz Res, https://doi.org/10.1016/j.schres.2018.01.002
). 
 The purpose of this study is to examine changes in serum butyrate levels with the prebiotic: Prebiotin (12g/day), an oligofructose- enriched inulin ( OEI); the effe ct of 
OEI on the composition of the gastrointestinal microbiota in people with 
schizophrenia; and the relationship of the composition of the gut microbiota to various clinical, cognitive, and neuroimaging variables.  
3. STUDY DESIGN  
In a sample of inpatien ts  with a DSM -IV-TR/DSM -5 diagnosis of schizophrenia or 
schizoaffective disorder, we will conduct a 10- day, double- blind, placebo- controlled, 
randomized clinical trial to examine the effect of a prebiotic, oligofructose- enriched inulin 
(OEI) on serum butyrate levels; the relative preponderance of butyrate- producing bacteria 
in the gut microbiome; and the relationship of these measures to cytokine or gut permeability measures,  signs and symptoms of schizophrenia, and/or metabolic measures. 
We will consent and evaluate up to 30 participants to reach the goal of approximately 24 
participants randomized and 20 study completers .  We will plan to randomize 
approximately 24 participants, because we anticipate a 10- 20% attrition rate.  We will 
consen t and evaluate up to 30 participants, because we anticipate that some participants, 
who provide informed consent, may not meet eligibility criteria. However, we do not expect to need to consent 30 participants, because potential participants will be prescr eened, 
through our partial HIPPA waiver, and those with obvious exclusion criteria (e.g. do not meet the age range criterion) will not undergo the informed consent process. Participants 
will be randomized to either OEI , 12 g/day or matching placebo, with a pproximately 10 
participants in each group. We will use an inpatient sample in order to standardize meals, exercise and environmental mediators. We will recruit patients from the Treatment Research Program inpatient unit, Maryland Psychiatric Research Center, University of Maryland School of Medicine.  
 
4. SELECTION AND ENROLLMENT OF PARTICIPANTS  
The overall goal of this project is to determine whether oligofructose- enriched inulin ( OEI) 
is an effective treatment for schizophrenia. We will use an inpatient  sample in order to 
standardize meals, exercise and environmental mediators. The population to be included will not include any people in prisons, but will include psychiatric inpatients who are court -
ordered for care. The research on understanding the gut  microbiota, as well as 
understanding if over the counter prebiotics may change the gut microbiota, have minimal inherent risk regardless of the court -ordered status of the research participants. This 
research, however, can only take place in a controlled living environment with all people receiving standardized meals and similar environmental influences to have unflawed 
Protocol Template, Version 6  18 of 54 results. Court -ordered patients comprise the majority of the inpatient psychiatric unit 
population. The environment at Spring Grove Hospit al Center is identical for both court -
ordered and non- court -ordered patients on the Treatment Research Unit.  
4.1 Inclusion Criteria  
Participants must meet all of the inclusion criteria to participate in this study:  
1) DSM -IV-TR /DSM -5 diagnosis of schizophren ia or schizoaffective 
disorder;  
2) Age 18- 60 years;  
3) Considered clinically stable by the treating psychiatrist;  
4) Currently treated with an antipsychotic, with no dose changes in last 14 
days;  
5) Ability to participate in the informed consent process, as determi ned by a 
score of 10 or greater on the Evaluation to Sign Consent;  
6)  BMI ≤ 40 
4.2 Exclusion Criteria  
All candidates meeting any of the exclusion criteria at baseline will be excluded 
from study participation:  
1) Gastrointestinal disorders, including, but not limited to Crohn’s Disease, 
Irritable Bowel Syndrome, Celiac Disease, whose pathology or treatment could alter the presentation or treatment of schizophrenia or significantly increase the risk associated wi th the proposed treatment protocol  
2) Organic brain disorder, including cerebrovascular accident; epilepsy; 
traumatic brain injury, Loss of consciousness (LOC) for more than 30 minutes  
3) Intellectual disability  
4) Acute a ntibiotic  use  
5) Immune therapy w ithin the last three months  
6) Prebiotic or probiotic treatment within the last three months  
7) Inability to understand English  
8) Inability to cooperate with study procedures  
9) Pregnant or lactati on secondary to pregnancy  
10) Meet DSM- 5 criteria for alc ohol or substance use disorders (except 
Tobacco Use Disorder) within last 3 months  
4.3 Study Enrollment Procedures   
Potential participants will be recruited from the MPRC Treatment Research Program, and will consist of people who are currently hospitalized on the TRP or 
who are admitted to the TRP over the course of the study. We chose to limit the 
study population to inpatients, so we could standardize the diet across participants 
in this phase of the project. Reasons for ineligibility or non- participation of eligible 
candidates will be documented in the Enrollment Log.  
 
Protocol Template, Version 6  19 of 54 The consent form will include an explanation of the risks and benefits of 
participation; assurances of confidentiality; and an explanation that participation is entirely voluntary, the dec ision to participate will in no way influence or restrict 
services at participating sites, and the participant is free to withdraw at any time without negative consequences. As some potential participants will have poor reading skills, the consent form wil l be read aloud to all participants in tandem with 
their own silent reading of the document. The individual securing consent will review any points about which the participant is unclear, and the participant will be invited to ask questions as needed. Our research staff is carefully trained in strategies for interacting with people with severe mental illness, including speaking slowly and clearly, stopping to summarize frequently, and providing time for questions. They are all supervised by senior staff mem bers. All participants who 
express willingness to provide consent will be queried about the consent form in order to ensure that they have adequate understanding of the study requirements.  This questioning is performed systematically, and research staff m embers 
document that this review has been completed. After reading the consent, and before obtaining a signature, a brief questionnaire is administered to verify that the participant is competent to provide consent and has demonstrated comprehension of the  consent document. This questionnaire is attached to the informed consent 
form and is completed immediately after explaining the informed consent form and before obtaining the participant's signature on the form. If the participant does not understand the consent form, the recruiter will try to explain points of confusion, and administer the questionnaire again. Those failing to answer the questions adequately will not be recruited into the study. The recruiter will also make a clinical judgment and not rec ruit participants who appear unable to grasp key aspects of 
the procedure. This approach, which requires a proactive demonstration on the part of the participant that they understand what is being requested, has been used extensively by investigators at th e MPRC. Included participants must also be 
judged competent to consent by the Evaluation to Sign Consent (ESC) questionnaire (DeRenzo et al 1998). Per University of Maryland School of Medicine IRB regulations, a copy of the signed consent form is given to the participant, a copy is placed in the person's medical record, and the original is kept by the PI.  
 Research assistants obtaining informed consent will be experienced clinicians. They will receive detailed and standardized training as to how to obtain informed 
consent from people with serious mental illnesses. They will be observed obtaining informed consent from a study participant by senior staff prior to being allowed to enroll participants on their own.  
 The study biostatistician will use a permuted block randomization system (block sizes 2 or 4), in which treatment assignment order is random within each block, 
with an equal number of participants assigned to each treatment, to generate a list 
of treatment assignments. Thus, it will be difficult to ascertain the next treatment 
assignment, even if a participant becomes unblinded, while any imbalance in the number of participants between the treatment groups will be kept within tight limits. All raters, investigators and other staff will be blind to treatment assignment except 
Protocol Template, Version 6  20 of 54 for the pharmacist. The pharmacist does not participate in the assessment of any 
of the primary symptom or side effect dependent variables and conveys no information about treatment assignment to participants or staff except  in a medical 
emergency.  
5. STUDY INTERVENTIONS  
5.1 Interventions, Administration, and Duration  
Participants who continue to fulfill inclusion criteria will enter the 10- day double-
blind treatment phase. Participants will be randomly assigned to OEI or placebo-
OEI, with approximately 10 participants in each group. Participants randomized to OEI will receive 4 grams of OEI , mixed in water, three times a day for 10 days. We 
chose the 12 grams/day dose, because a previous study suggests that this dose is 
well tolerated and based on data from a pilot study conducted by our co-
investigators. Participants randomized to placebo will receive maltodextrin (4 
grams), mixed in water, three times a day for 10 days. Maltodextrin is a 
polysaccharide composed of glucose units, a mixture of chains that vary from 3 to 
17 glucose units long; and is freely soluble or readily dispersible in water and is a quickly digested carbohydrate. Maltodextrin has previously been used in studies evaluating the effect of OEI prebiotics (A brams et al, 2005; Casellas et al, 2007; 
Roller et al, 2007; De Peter et al, 2008; Dehghan et al, 2014), and produces minimal changes in inflammatory and metabolic measures (Casellas et al, 2007; Dehghan et al, 2014).  
5.2 Handling of Study Interventions   
The OEI will be provided in bulk by Jackson GI Medical in the form of Prebiotin. 
OEI is considered a food supplement and is being used for its indication to improve 
gut bacteria composition, thus it is not a drug product nor is it being used for any other indication. Maltodextrin and OEI have a similar appearance when dissolved 
in water and both have a slightly sweet taste, which will help to preserve the blind. A non -blind pharmacist will dispense all study medications. The blind will be broken 
only if a m edical emergency requires this information.  
In order to monitor compliance, participants will be observed by research staff while they ingest the study medication. Since all participants will be inpatients, we do not expect problems with compliance, but w e will carefully monitor compliance 
patterns, which will be described within each treatment group as part of any presentation of study results.  
5.3 Concomitant Interventions   
5.3.1  Allowed Interventions  
Participants may continue taking their prescribed ant ipsychotic, with no dose 
changes in the 14 days prior to signing consent.  
Protocol Template, Version 6  21 of 54 5.3.2  Required Interventions  
N/A 
5.3.3  Prohibited Interventions  
Participants may not have been taking antibiotic or immune therapy, or 
prebiotic or probiotic treatment within the las t three months prior to signing 
consent.  
5.4 Adherence Assessment  
We will strive to ensure that all participants receive ≥ 90% of their assigned 
medication. The 90% criterion increases the likelihood that participants will receive adequate treatment to ev aluate the effect of OEI on the biological signature. In 
order to monitor adherence, participants will be observed by research staff while they ingest the study medication. Since all participants will be inpatients, we do not expect problems with adherence, but we will carefully monitor adherence patterns, which will be described within each treatment group as part of any presentation of study results.  
6. STUDY PROCEDURES  
6.1 Schedule of Evaluations  
Schedule of Events  2-Week 
Evaluation 
Phase  Baseline, Enrollment, 
Randomization  Double -Blind 
Treatment Phase  
Encounter # →  P1V1  P2V0  P2V1   P2V2  P2V3  
Day of Study →  Day -14 to -1 
 Day -1 Day 0  
 Day 
1-9 Day 
10 
 Day 
11 
Procedure ↓        
Informed consent and 
ESC X      
Eligibility Documentation  X      
Protocol Initiation Sheet X      
Recommendation for 
Inclusion Form  X      
Brief Psychotropic 
Medications Form  X     X 
Brief Non -Psychotropic 
Medications Form  X     X 
Demographic Forms  X      
Fagerstrom, short 
version  X      
SCID -Interview*  X      
Protocol Template, Version 6  22 of 54 Medical History and 
EKG**  X      
Physical Exam and 
height**  X      
Diet Log  X      
CMP -14, CBC  Lipid 
Panel  X     X 
UA; Urine Pregnancy 
Test (females)  X     X 
Side Effect Checklist    X  X  
BPRS    X   X 
HAM -A   X   X 
Cytokines, C -reactive 
protein    X   X 
ASCA and AGA IgG    X   X 
Tryptophan, Kynurenine, 
KYNA & 3 -HK   X   X 
OEI Challenge    X   X 
Serum Butyrate: pre -
prandial, 2 hr and 6 hr 
after OEI challenge    X   X 
OEI or Placebo (Day1 -
10)    X X  
Fully Digestible Meal   X   X  
Stool Sample Collection   X   X  
Vital Signs, including 
weight, BP and pulse  X X X  X X 
Protocol Participation 
Status Sheet X X X  X X 
 
*SCID interview results may be used, if completed within the past 5 years. The Drug Misuse section still needs to re- done at time of visit.  
 **Medical history, EKG, physical exam, height and other screening and baseline measures can be collected from the TRP admission assessment if completed within the past 2 months.  
Protocol Template, Version 6  23 of 54 6.2 Description of Evaluations   
Once participants sign the informed consent form, they will enter a 2- week 
Evaluation Phase (Screening and Baseline), during which they will undergo 
baseline medical, vital sign, and symptom assessments to determine whether they meet inclusion criteria. This will include a comprehensive medical history and 
physical examination. We will obtain baseline CBC, Chemistry -14 Panel, lipid panel 
and urinalysis assessments. Weight, height and vital signs (i.e., heart rate, pulse, blood pressure) will be assessed weekly throughout the study. The diagnosis of schizophrenia or related disorder will be confirmed by a structured psychiatric examination, the Structured Clinical Interview for DSM -5. Participants will also have 
baseline symptom assessments completed. Partici pants continuing into the 
Double- blind Treatment phase will repeat baseline symptom assessments during 
week 2. All participants will receive the identical, standardized diet, provided by a registered dietician, which will consist of 3 meals and one or two snacks.  The daily 
diet breakdown is approximately 2700 calories with the following composition: 100 g protein, 400 g carbohydrates, 28 g fiber, 6.7% saturated fat, 28% total fat, 240 mg cholesterol and 4.4 g sodium.  
 Participants who continue to fulfill inclusion criteria will enter the 10- day double-
blind treatment phase. Participants will be randomly assigned to OEI or placebo-
OEI, with approximately 10 participants in each group. The OEI  will be provided by 
Jackson GI Medical in the form of Prebiotin. OEI is considered a food supplement 
and is being used for its indication to improve gut bacteria composition, thus it is not a drug product nor is it being used for any other indication. Participants 
randomized to OEI will receive 4 grams of OEI , mixed in wa ter, three times a day 
for 10 days. We chose the 12 grams/day dose, because a previous study suggests 
that this dose is well tolerated and based on data from a pilot study conducted by our co- investigators. Participants randomized to placebo will receive m altodextrin 
(4 grams), mixed in water, three times a day for 10 days. Maltodextrin is a polysaccharide composed of glucose units, a mixture of chains that vary from 3 to 17 glucose units long; and is freely soluble or readily dispersible in water and is a quickly digested carbohydrate. Maltodextrin has previously been used in studies evaluating the effect of OEI prebiotics (Abrams et al, 2005; Casellas et al, 2007; 
Roller et al, 2007; De Peter et al, 2008; Dehghan et al, 2014), and produces minimal changes in inflammatory and metabolic measures ( Casellas et al, 2007; 
Dehghan et al, 2014). Maltodextrin and OEI have a similar appearance when 
dissolved in water and both have a slightly sweet taste, which will help to preserve the blind. A non- blind pharmacist will dispense all study medications. The blind will 
be broken only if a medical emergency requires this information. If this occurs, the participant will be withdrawn from the study.  
 
In order to evaluate the impact of OEI treatment, we will examine change in serum 
butyrate levels following treatment. There will be two test days: a) baseline (Day 0), 
prior to randomization to OEI  or placebo; and b) Day 11, following the 10 day 
course of  OEI/placebo treatment. We will use OEI for the inulin challenge. On the 
night prior to each test day, participants will receive a completely digestable and 
non-fermentable meal, e.g. lasagna  and up to two fully digestable snacks (e.g. 
Protocol Template, Version 6  24 of 54 chips) . They will th en fast from midnight until the morning, when they will receive 
their standard , low- fiber breakfast and OEI , 12g. We will collect fasting, 2 hour and 
6-hour blood samples from each participant. Participants will be able to receive a 
light digestable meal 4 hours after OEI  administration.  The Day 11 change in 
serum butyrate levels following the OEI  challenge dose (2 or 6- hour minus fasting 
morning serum butyrate level) will be compared to the Day 0 change in serum 
butyrate levels to determine whether the 10- day OEI treatment regimen modified 
the hypothesized biological signature through increased activity of butyrate-producing bacteria. Serum butyrate will be quantified by LC -MS/MS, conducted by 
the School of Pharmacy Mass Spectrometry Center.  
 
6.2.1  Screenin g Evaluation  
Consenting Procedure  
Before any screening procedure is performed, informed consent must be obtained.  
There will be a single informed consent form that describes both the screening and study procedures.  
 Research assistants obtaining informed consent will be experienced clinicians. 
They will receive detailed and standardized training as to how to obtain informed consent from people with serious mental illnesses. They will be observed obtaining informed consent from a study participant by senior staff prior to being allowed to enroll participants on their own.  
 The consent form will include an explanation of the risks and benefits of 
participation; assurances of confidentiality; and an explanation that participation is entirely voluntary , the decision to participate will in no way influence or restrict 
services at participating sites, and the participant is free to withdraw at any time without negative consequences. As some potential participants will have poor reading skills, the consent  form will be read aloud to all participants in tandem with 
their own silent reading of the document. The individual securing consent will review any points about which the participant is unclear, and the participant will be invited to ask questions as needed. Our research staff is carefully trained in strategies for interacting with people with severe mental illness, including speaking slowly and clearly, stopping to summarize frequently, and providing time for questions. They are all supervised by senior staff members. All participants who express willingness to provide consent will be queried about the consent form in order to ensure that they have adequate understanding of the study requirements.  
This questioning is performed systematically, and researc h staff members 
document that this review has been completed. After reading the consent, and 
before obtaining a signature, a brief questionnaire is administered to verify that the participant is competent to provide consent and has demonstrated comprehensi on 
of the consent document. This questionnaire is attached to the informed consent form and is completed immediately after explaining the informed consent form and before obtaining the participant's signature on the form. If the participant does not unders tand the consent form, the recruiter will try to explain points of confusion, 
and administer the questionnaire again. Those failing to answer the questions 
Protocol Template, Version 6 25 of 54 adequately will not be recruited into the study. The recruiter will also make a clinical 
judgment an d not recruit participants who appear unable to grasp key aspects of 
the procedure. This approach, which requires a proactive demonstration on the part of the participant that they understand what is being requested, has been used extensively by investigators at the MPRC. Included participants must also be judged competent to consent by the Evaluation to Sign Consent (ESC) questionnaire (DeRenzo et al 1998). Per University of Maryland School of Medicine IRB regulations, a copy of the signed consent form is given to the participant, a copy is placed in the person's medical record, and the original is kept by the PI. Consent for each participant will be documented on the Documentation of Consent (DOC) form.  
Screening 
Once participants sign informed consent they will enter a 2- week Evaluation Phase 
(P1V1, Days - 14 to - 1)), during which they will undergo baseline medical, vital sign, 
and symptom assessments to determine whether they meet inclusion criteria. 
Psychiatric, Medical history, EKG, physical exam, height and other screening and baseline measures can be collected from the TRP admission assessment if completed within the past 2 months.  
This will include:  
• Demographic information: Documentation of age eligibility  
• SCID- Interview : The diagnosis of schizophrenia from the medical record will 
be confirmed by a structured psychiatric examination, the Structured Clinical Interview for DSM -5. The SCID interview can be re -used if completed within 
the past 5 years, with the Drug Misuse section re- completed at time of visit.  
• Medical and safety assessments to rule out excluded medical conditions and determine any clinically significant abnormal laboratory values:  
o Medical history  
o Physical examination  
o Electrocardiogram (EKG)  
o CBC 
o Fasting chemistry panel  
o Lipid panel  
o Urinalysis assessments including a pregnancy test for females  
o Vital signs : Blood pressure, heart and respiratory rates, height and 
weight, prior to randomization to the intervention; weight and height measurements will be used to calculate BMI, which must be less than ≤ 40 for eligibility.  
• D
ietary assessment : We will review the  diet of each participant for up to a 
week prior to their study entry.  
• Smoking form: Document smoking status of participants.  
Protocol Template, Version 6 26 of 54 • Recommendation for Inclusion Form: Documents clinical stability, absence 
of a history of intellectual disability, and ability to cooperate with study 
procedures.  
• Psychotropic and non- psychotropic concomitant medication forms: We will 
document all current medications including dosage, date started, and route of administration.  
• Stool Sample: Participants will provide a baseline stool  sample prior to the 
initiation of study medication.  
6.2.2  Enrollment, Baseline, and/or Randomization 
Enrollment  
Enrollment is defined as the randomization date, which will be recorded on a case report form and entered into the study database. The allowable window between screening and randomization is 14 days.  
Baseline Assessments 
For participants who have successfully been screened for eligibility and are 
enrolled into the study, baseline assessments are performed against which to measure the study outcome (P2/V1, Day 0). Participants who continue to fulfill inclusion criteria will enter the 10- day double- blind treatment phase. Participants 
will be randomly assigned to OEI or placebo- OEI, with approximately 10 
participants in each group.  
• OEI Challenge : On the night prior to each test day, participants will receive a 
completely digestible and non- fermentable meal, e.g. lasagna.  They will 
then fast from midnight until the morning, when they will receive their standard breakfast and OEI, 12g.  
• S
erum Butyrate : In order to evaluate the impact of OEI  treatment, we will 
examine change in serum butyrate levels following treatment. We will collect 
baseline, 2- hour and 6 -hour blood samples from each participant. The blood 
samples will be analyzed at the University of Maryland School of Pharmacy Mass Spect rometry Center.  
• T
he Brief Psychiatric Rating Scale (BPRS; Overall and Gorham 1962) : the 
BPRS total score will be used to measure global psychopathology. The four BPRS positive symptom items - conceptual disorganization, suspiciousness, 
hallucinatory behavior, and unusual thought content - will be used to 
measure positive psychotic symptoms.  
• Ha
milton Anxiety Rating Scale (HAM -A; Seedat et al, 2007) : The HAM -A will 
be used to measure symptoms of anxiety.  
• P eripheral Cytokines and Other Laboratory Measures : Serum cytokines; 
highly sensitive C -reactive protein (CRP); and adiponectin and leptin. Serum 
cytokines will be measured by the Cytokine Core Laboratory at the University of Maryland using Luminex® 100 Multianalyte System or ELISA at baseline and endpoint or  the Immune Lab at Johns Hopkins. The primary 
cytokines to be analyzed initially will be IL -1β, IL -6, and TNF -α, and the 
acute phase protein C -reactive protein (CRP), which is induced by increased 
Protocol Template, Version 6 27 of 54 cytokine levels, including IL- 6. The other cytokines listed will be initially 
stored and analyzed at a later date.  
• ASCA and AGA IgG : We will use Anti- Saccharomyces Cerevisiae 
Antibodies (ASCA) to measure the integrity of the gut -blood barrier. ASCA 
are antibodies that develop against antigens presented by the cell wall of the 
yeast, Saccharomyces cerevisiae. ASCA are elevated in people with intestinal inflammation (e.g. Crohn’s Disease) and increased intestinal permeability (Rutgeerts and Vermeire, 1998; Makharia et al, 2007), which supports their use as a marker of increased intestinal permeability (Irvine et 
al, 2000; Barta et al, 2003). AGA IgG antibodies have been found to be 
present in about 1/3 people with schizophrenia and linked to diseases such 
as celiac disease and gluten sensitivity and ar e known to modulate gut 
bacteria and potentially butyrate.  ASCA IgA and IgG will be measured, using 
the protocol of the commercially available ELISA kit (Orgentec, Mainz, Germany). We will collect ASCA levels at baseline and the end of week 10.   We will a lso measure Antigliadin Antibodies (AGA IgG).  The blood samples 
will be analyzed at the University of Maryland School of Pharmacy Mass Spectrometry Center.  
• V
ital Signs : Blood pressure, heart and respiratory rates, height and weight, 
prior to randomization to the intervention; weight and height measurements will be used to calculate BMI.  
• S
ide Effect Checklist (SEC) : The SEC will be used to assess the baseline 
presence of potential side effects.  
Randomization 
The study biostatistician will use a permuted block randomization system (block 
sizes 2 or 4), in which treatment assignment order is random within each block, with an equal number of participants assigned to each treatment, to generate a list of treatment assignments. Thus, it will be difficult to ascertain the next treatment assignment, even if a participant becomes unblinded, while any imbalance in the number of participants between the treatment groups will be kept within tight limits.  
6.2.3  Blinding 
All study clinical, laboratory, medical  and safety assessments will be done by 
research assistants, who are blind to treatment assignment. The study biostatistician will be blinded until the final lock of the database. The P.I. and the co-investigators will be blinded until all study analyses have been completed.  
 Only the research pharmacist will be unblinded. The research pharmacist will be responsible for requesting the treatment assignment from the study biostatistician, who will use a permuted block randomization system (block sizes 2 or 4), in which treatment assignment order is random within each block, with an equal number of participants assigned to each treatment, to generate a list of treatment assignments. The research pharmacist will be responsible for preparing the study interventi ons based on the treatment assignment he receives from the 
biostatistician. Maltodextrin and OEI  have a similar appearance when dissolved in 
water and both have a slightly sweet taste, which will help to preserve the blind. 
Protocol Template, Version 6  28 of 54 The study biostatistician will h ave no access to the data, nor will he have any 
influence on the conduct of any of the outcome assessments.  
 
The blind will be broken only if a medical emergency requires this information.  
The data analyst will be blinded to treatment assignment and will prepare any requested blinded reports for the Data Safety Monitoring Board (DSMB) . If the 
DSMB request s unblinded study reports, then the data analyst will work with the 
DSMB to prepare these reports (see attached DSMB roster: Appendix III).  
 
6.2.4  Double -Blind Treatment Phase  
Study visits must be performed on the weeks indicated in the Schedule of 
Evaluations.  
• Days 1 -9: 
 OEI or Placebo  
 Stool Sample (after Day 5)  
• Day 10 (P2V2):  
 OEI or Placebo  
 Vital signs  
 SEC 
6.2.5  Completion/Final Evaluation 
• Day 11 (P2V3):  
 OEI Challenge  
 CBC 
 Fasting chemistry panel  
 Lipid panel  
 Urinalysis assessments including a pregnancy test for females  
 BPRS  
 HAM -A 
 Peripheral cytokines and other laboratory measures (C -reactive protein, 
Tryptophan, Kynurenine, KYNA, a nd 3- HK) 
 ASCA and AGA IgG  
 Serum butyrate  
 Vital signs  
 Psychotropic and non- psychotropic concomitant medications  
The DSMB or IRB will conduct a safety review of AE's and SAE's, which will yield a decision to cease enrollment for the study. Participants may also request to be withdrawn from the study at any time. Once a participant is discontinued from the 
Protocol Template, Version 6 29 of 54 study for whatever reason, completion ratings will be performed if possible. This 
includes all laboratory tests and rating scales below. The study team will record all reportable events with start dates occurring any time after informed consent is obtained until the last day of study participation, or until the resolution or stabilization 
of an event. At each study visit, the study team will inquire about the occurrence of AE/SAEs since the last visit.  Events will be followed for outcome information until resolution or stabilization.  
7. SAFETY ASSESSMENTS  
Participant safety will be monitored once an individual is enrolled in the study. The study medication, OEI in the form of Prebiotin , may be associated with adverse effects. The 
most common side effects are flatulence, bloating, and abdominal discomfort.  We will 
make every attempt to minimize all study -related risks. We will carefully monitor patients 
and psychiatric symptoms throughout the study. All patients are in the inpatient setting 
with 24 monitoring and care. 
7.1 Specification of Safety Parameters  
All participants will receive a complete medical history and physical examination, including vital signs: blood pressure, heart and respiratory rates, height and weight, prior to randomization to the intervention; weight and height measurements will be used to calculate BMI. We will collect baseline EKG  and baseline and end of 
study CBC; complete metabolic panel (CMP), including BUN/Creatinine, 
electrolytes, glucose, LFTs, and lipid panel; and U/A asses sments. The CMP will 
be collected after fasting for at least 8 hours. Female participants of child- bearing 
potential will have a pregnancy test at baseline and Day 11 .   
 The Side Effect Checklist (SEC) is designed to assess medication side effects commonl y associated with pharmacological treatments. In addition, if not already 
assessed, the SEC is modified for the purpose of the assessment of specific side effects associated with the particular intervention under study; in this case OEI . 
The SEC version to be used in the proposed study rates 35 potential side effects, 
and comprehensively covers the side effects that have been previously reported with OEI, i.e., bloating, flatulence, and abdominal pain. In addition, there are three 
“other” spaces for idiosyncratic participant complaints, which are not usually associated with medication treatment. The SEC will be conducted at baseline and Day 1 0. 
7.2 Methods and Timing for Assessing, Recording, and Analyzing Safety Parameters  
OEI is considered a food supplement and is being used for its indication to improve 
gut bacteria composition, thus it is not a drug product nor is it being used for any other indication. Participants randomized to OEI  will receive 4 grams of OEI , mixed 
in wat er, three times a day for 10 days. We chose the 12 grams/day dose, because 
a previous study suggests that this dose is well tolerated and based on data from a pilot study conducted by our co- investigators.  
 
Protocol Template, Version 6  30 of 54 Participants randomized to placebo will receive maltodextrin (4 grams), mixed in 
water, three times a day for 10 days. Maltodextrin is a polysaccharide composed of glucose units, a mixture of chains that vary from 3 to 17 glucose units long; and is freely soluble or readily dispersible in water and is a  quickly digested carbohydrate. 
Maltodextrin has previously been used in studies evaluating the effect of OEI  
prebiotics (Abrams et al, 2005; Casellas et al, 2007; Roller et al, 2007; De Peter et al, 2008; Dehghan et al, 2014), and produces minimal changes  in inflammatory and 
metabolic measures (Casellas et al, 2007; Dehghan et al, 2014).  
7.3 Adverse Events and Serious Adverse Events  
An adverse event (AE)  is any untoward medical occurrence in a participant during 
participation in the clinical study or wit h use of the experimental agent being 
studied. An adverse finding can include a sign, symptom, abnormal assessment 
(laboratory test value, vital signs, electrocardiogram finding, etc.), or any combination of these regardless of relationship to participation in the study. Adverse events are to be recording regardless of their relationship to the study intervention.   
A serious adverse event (SAE) is one that meets one or more of the following 
criteria:  
• Results in death.  
• Results in persistent or significant disability/incapacity.  
• Results in or prolongs an existing inpatient hospitalization (even if the 
hospitalization is a precautionary measure for observation).  
• Is a congenital anomaly/birth defect in offspring of subjects taking the product 
regardless of time to diagnosis.  
• Is cancer.  
• Is the result of an overdose, whether accidental or intentional.  
• Is a suicide attempt (not suicidal ideation only).   An important medical event that may not result in death, be life threatening, or require hospitalization may be considered an SAE when, based upon appropriate 
medical judgment, the event may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.  
 
The study team will rec ord all reportable events with start dates occurring any time 
after informed consent is obtained until the last day of study participation, or until 
the resolution or stabilization of an event. At each study visit, the study team will inquire about the occ urrence of AE/SAEs since the last visit.  Events will be 
followed for outcome information until resolution or stabilization.  
 Laboratory assessments that we will collect are EKG; CBC; complete metabolic panel (CMP), including BUN/Creatinine, electrolytes, glucose, LFTs, and lipid panel; and U/A assessments. Female participants of child- bearing potential will 
have a pregnancy test .  Clinically significant abnormal laboratory values are 
defined as any values outside the reference range for a laboratory.  
 
Protocol Template, Version 6  31 of 54 The Side Effect Checklist (SEC) is designed to assess medication side effects 
commonly associated with pharmacological treatments . In addition, if not already 
assessed, the SEC is modified for the purpose of the assessment of specific side effects associated with the particular intervention under study; in this case OEI . 
The SEC version to be used in the proposed study rates 35 pote ntial side effects, 
and comprehensively covers the side effects that have been previously reported with OEI, i.e., bloating, flatulence, and abdominal pain. In addition, there are three 
“other” spaces for idiosyncratic participant complaints, which are not  usually 
associated with medication treatment. The SEC rates each side effect on a 4- point 
scale ( 1: none to 4: severe).  The SEC will be conducted at baseline and Day 10.  
 
 The following definitions will be used to define an adverse event:  
• Any SEC item for which there is a two-point  increase over the baseline 
assessment of the item; and  
• Any SEC item that is rated “4” at Day 10, but  was not rated “4” in the baseline 
assessment.  
7.4 Reporting Procedures  
The Study PI and Independent Monitoring Committee will be responsible for determining whether an AE is expected or unexpected. An adverse event will be considered unexpected if the nature, severity, or frequency of the event is not consistent with the risk  information previously described for the intervention.   
To assess relationship of an event to study intervention, the following guidelines are used:  
1. Related (Possible, Probable, Definite)  
a. The event is known to occur with the study intervention.  
b. There is a temporal relationship between the intervention and event onset.  
c. The event abates when the intervention is discontinued.  
d. The event reappears upon a re- challenge with the intervention.  
2. Not Related (Unlikely, Not Related)  
a. There is no temporal relationship b etween the intervention and event 
onset.  
b. An alternate etiology has been established.  
 
The following scale will be used to grade adverse events  when reporting to the 
Data  Safety Monitoring Board. This scale is used when reporting all adverse 
events, includi ng side effects assessed with the SEC : 
1. Mild: no intervention required; no impact on activities of daily living (ADL)  
(SEC item score= 2) 
2. Moderate: minimal, local, or non- invasive intervention indicated; moderate 
impact on ADL (SEC item score=3)  
3. Severe: significant symptoms requiring invasive intervention; subject seeks medical attention, needs major assistance with ADL (SEC item score=4)  
 
Protocol Template, Version 6 32 of 54 Serious adverse events will be reported to the DSMB, the UMB IRB, and NCCIH by 
the Principal Investigator (P.I.) or their designated POC in accordance with requirements.   
• All serious AEs will be reported to the NCCIH Program Officer, the DSMB, and the UMB IRB within 3 business days of the investigator becoming aware of the event. Any follow -up reports are to be submitted as new information 
regarding the event becomes available. Adverse events that are determined to be unexpected and probably related to study procedures, regardless of severity, will be reported to NCCIH and the UMB IRB within 5 business days. These AEs will be reported to the DSMB with the annual report.  
• Anticipated or unrelated AEs will be handled in a less urgent manner but will be reported to the DSMB, UMB IRB, and to NCCIH on an annual basis.    
Incidents of pregnancy will be reported to all oversight committees along with the annual reports. Participants determined to be pregnant will be withdrawn from the study.  
7.5 Follow -up for Adverse Events  
At each study visit, the study team will inquire about the occurrence of AE/SAEs since the last visit. Events will be followed for outcome information until resolution or stabilization.  
7.6 Safety Monitoring   
The Data and Safety Monitoring Board (DSMB) for this study consists of two 
research/practicing psychiatrists; one community psychiatrist; one internal and one 
external biostatistician and one research pharmacist.   
 
The DSMB will 1) review proposed protocols and consent forms prior to the start of 
enrollment to assess how the PI will report adverse events, early withdrawals and 
terminations; 2) evaluate recruitment and rate of enrollment in relation to study 
targets; 3) monitor the occurrence of adverse events, serious adverse events, and 
early withdrawals or terminations; 4) evaluate study outcomes, when available; 5) 
monitor study throughout its progress.  Any serious adverse event (SAE) that 
occurs to a subject enrolled in this study will be reported to the DSMB within 5 
working days; or within 48 hours if it is directly related to the research interv ention. 
Unexpected adverse events will be reported in accord with NIH and Federal 
requirements. Non- serious, expected adverse events will be reported annually to 
the IRB. Once a protocol has been initially reviewed, the DSMB will determine the 
frequency of  review for the study, at minimum yearly.  
 
The DSMB will review with the research team the data management system and 
study progress. This DSMB has existed for over 10 years and has monitored 
numerous protocols. The DSMB will receive side effect/adverse event updates 
whenever this protocol is discussed (although we do not expect any treatment 
related adverse events since the treatment and the measurements have minimal or 
no risk). Any serious adverse events (SAEs) will be reported to governing 
authorities per each agency’s established guidelines.  
Protocol Template, Version 6  33 of 54 8. INTERVENTION DISCONTINUATION  
The DSMB or IRB will conduct a safety review of AE's and SAE's, which will yield a 
decision to continue or terminate the study.  
 Participants may request to be withdrawn from the study at any time, either because of an inability to tolerate the study medication or some other reason. Once a participant is discontinued from the study medication, for whatever reason, we will make every  attempt 
to complete the remainder of the scheduled assessments. This includes laboratory tests and rating scales.  
 
9. STATISTICAL CONSIDERATIONS  
9.1 General Design Issues   
We hypothesize that OEI, compared to placebo, will produce a greater increase in 
serum butyrate levels secondary to the stimulatory effects of OEI  on the activity of  
known butyrate- producing bacteria.  
 
Our hypothesis will be confirmed if either item 1 or 2 are met:  
1. The relative response rate of OEI  responders to placebo responders is ≥ 
3 for the between group comparison of the end of study post -inulin 
challenge butyrate level to the baseline post -inulin challenge butyrate 
level. "Responders" will be defined as those whose change in post -/pre-
OEI treatment increases in serum butyrate levels following the inulin 
challenge is >20%.  
2. The effect size of the change in pre- inulin challenge serum butyrate 
levels between treatment groups is ≥ 0.4 and the relative response rate 
is ≥ 3, with “responder” defined as a 10% difference in change in serum 
butyrate levels following the inulin challenge.  
• Note that we will not propose a transition if one of the above 
biomarker(s) achieves a medium effect size (defined as Cohen’s d 
≥ 0.5) in the opposite direction of predi ction  
 
If one or the other of the response criterion is met, then we would request a 
transition to the R33 phase.  
9.2 Sample Size and Randomization 
Sample Size  
The proposed sample size is 20; the participants will be of either sex and any race, 
and between 18- 60 years old. They will meet Diagnostic and Statistical Manual of 
Protocol Template, Version 6 34 of 54 Mental Disorders (DSM) -5 criteria for schizophrenia or schizophreniform or 
schizoaffective disorder.  
Treatment Assignment Procedures  
The study biostatistician will use a permuted block randomization system (block 
sizes 2 or 4), in which treatment assignment order is random within each block, with an equal number of participants assigned to each treatment, to generate a list of treatment assignments. Thus, it will be difficult to ascertain the next treatment assignment, even if a participant becomes unblinded, while any imbalance in the number of participants between the treatment groups will be kept within tight limits. All raters, investigators and other staff will be blind to treatment assignment except for the pharmacist. The pharmacist does not participate in the assessment of any of the primary symptom or side effect dependent variables and conveys no information about treatment assignment to participants or staff except in a medical emergency. The non- blind pharmacist will dispense all study medications. The 
blind will be broken only if a medical emergency requires this information.  
9.3  Definition of Populations  
All participants who are randomized will be included in the primary outcome 
efficacy analyses.  
All participant s who receive at least one dose of the proposed intervention will be 
included in the safety analyses.  
9.4 Interim Analyses and Stopping Rules  
We do not plan to conduct interim analyses on any of our primary or secondary outcome measures.  
 This study will be stopped prior to its completion if: (1) the intervention is associated with adverse effects that call into question the safety of the intervention; (2) difficulty in study recruitment or retention will significantly impact the ability to evaluate the study endpoints; (3) any new information becomes available during the trial that necessitates stopping the trial; or (4) other situations occur that might warrant stopping the trial.  
9.5 Outcomes  
Data collected for this study will be entered into the MPRC research data base using the usual procedures developed for MPRC clinical trials. This study will be reviewed by the UMB IRB and by a Data Safety Monitoring Board (DSMB).  The 
DSMB will evaluate study outcomes when they become available. All members of the committee will be masked to individual participants’ treatment assignments.  
 
9.5.1  Primary Outcome   
The primary outcome will be the change in serum butyrate levels from baseline to 
Day 11 (i.e., post 1 0 days of OEI treatment). We will measure serum butyrate 
levels on the two inulin challenge test days: a) baseline (Day 0), prior to 
Protocol Template, Version 6 35 of 54 randomization to OEI  or placebo; and b) Day 11, following the 10- day course of 
OEI/placebo treatment.  
 9.5.2  Secondary Outcomes   
N/A 
9.6 Data Analyses  
We will use an intent -to-treat approach to evaluate the change in butyrate 
production following 10 days of OEI treatment. We will use two approaches to 
assess the effect of OEI  on serum butyrate levels: 1) we will compare end of study 
to baseline changes in serum butyrate levels following an inulin challenge; and 2) 
we will compare baseline pre- inulin challenge serum butyrate to end of study pre-
inulin challenge serum butyrate levels. A clinically meaningful change in the response to the inulin challenge will be evaluated through the comparison of the relative response rate to treatment; the relative response rate is the ratio of ( OEI 
responders/all OEI participants) to (placebo responders/all placebo participants) , 
and is statistically analogous to calculating the relative risk. We will define 
"responders" as those whose change in post -/pre-OEI treatment increases in 
serum butyrate levels following the inulin challenge is >20%. W e chose the 20% 
criterion for responder, because we wanted to minimize the potential for false positives.  
We will also evaluate the effect of OEI on serum butyrate levels through the 
comparison of baseline and end of study pre -inulin challenge serum butyr ate 
levels. We will measure the butyrate levels the morning of the inulin challenge 
days, prior to the administration of the inulin. All participants will have received the same standardized meal the night before the blood draw.  
If the relative response r ate of OEI  responders to placebo responders is ≥ 3 (e.g. 8 
of 10 OEI  participants are responders versus 2 of 10 placebo participants are 
responders),  then we would meet our Go/No -go criterion for proceeding to the R33 
study. We would have power ≥82% to det ect a significant difference in the 
biological signature between the two groups in the proposed R33 study. If the relative response rate is < 3, then we will examine the change in pre-inulin 
challenge serum butyrate levels. If the effect size of the change in pre -inulin 
challenge serum butyrate levels between treatment groups is ≥ 0.4 and the relative 
response rate is ≥ 3, with “responder” defined as a 10% difference in change in 
serum butyrate levels following the inulin challenge, then we would consider t his 
adequate evidence for an effect of OEI on our biological signature and would 
request to proceed to the R33 study.  
We will review the extent of missing data for each of the demographic, clinical, and 
outcome variables. If needed, we will impute missing data by multiple imputation 
(MI). The assumption of missing at random (MAR) will be used. A sensitivity 
analysis will be performed to assess the MI.   
Protocol Template, Version 6 36 of 54 10. DATA COLLECTION AND QUALITY ASSURANCE  
10.1 Data Collection Forms   
Blinded research staff, including therapists, a nurse, and a pharmacist, will collect 
and record information for each participant on the CRF’s. Careful procedures  will 
be used to protect the privacy of participants and the confidentiality of the data.   Names will only appear on consent forms and on a master list that links them 
with study ID numbers (different from medical record numbers). This list will be stored in locked files in a separate location from the data.   At the conclusion of the 
project, the list will be destroyed, unless continuation is planned and approved by the Institutional Review Board. All data (whether on forms or electronic data files) will be  collected, analyzed, and reported according to the study ID -number and will 
contain no names or other personal identifiers. Paper -based data will be stored in 
locked files.  Electronic data files reside on desktop computers and are password 
protected.  
10.2 Data Management   
Data collected for this study will be recorded on paper Case Report Forms (CRF’s), then entered into the MPRC research data base using the usual procedures developed for MPRC clinical trials. This study will be reviewed by the UMB IRB and by a Data Safety Monitoring Board (DSMB). The DSMB will review this study at least annually. If there are any concerns about study safety, then the DSMB may choose to review the study more frequently.  Meeting minutes will be reported to 
the UMB IRB on an  annual basis. The DSMB consists of two research/practicing 
psychiatrists; one community psychiatrist; one internal and one external 
biostatistician and one research pharmacist.   
 
10.3 Quality Assurance  
10.3.1  Training  
At the beginning of the protocol, the PI and senior research staff will hold a study Protocol Initiation Meeting (PIM). At this time all study aspects are reviewed and all personnel working on the project attend. This meeting details the procedures of the study. We also develop s tandard operating procedures for the study and assign a 
primary research staff member to keep all information up to date. All personnel are told of their role on the study and we hold regular meetings with research personnel to go over study procedures and progress. In addition, all MPRC faculty 
and staff receive ongoing training on a variety of research issues yearly.  
 
10.3.2  Quality Control Committee  
This study will have a Data Safety Monitoring Board.  The DSMB will review this study at least annually.  DSMB meeting minutes will be sent to the IRB of record 
and the NCCIH program officer on an annual basis.  
 Careful procedures will be used to protect the privacy of participants and the confidentiality of the data. Names will only appear on consent forms and on a 
Protocol Template, Version 6  37 of 54 master list that links them with study ID numbers (different from medical record 
numbers). This list will be stored in locked files in a separate location from the data. At the conclusion of the project, the list will be destroyed, unless continuat ion is 
planned and approved by the Institutional Review Board. All data (whether on forms or electronic data files) will be collected, analyzed, and reported according to the study ID number and will contain no names or other personal identifiers. Paper -
based data will be stored in locked files. Electronic data files reside on desktop computers and are password protected.  
 
10.3.3  Metrics  
We will strive to ensure that all participants receive ≥ 90% of their assigned 
medication. The 90% criterion increases the likelihood that participants will receive 
adequate treatment to evaluate the effect of OEI on the biological signature. In 
order to m onitor adherence, participants will be observed by research staff while 
they ingest the study medication. Since all participants will be inpatients, we do not 
expect problems with adherence, but we will carefully monitor adherence patterns, which will be d escribed within each treatment group as part of any presentation of 
study results.  
 
10.3.4  Protocol Deviations  
Protocol deviations for any reason will be captured on a Study Deviation Log. Failure to follow the protocol due to the action or inaction of the investigator or 
research staff will be reported to the oversight IRB and the NCCIH program officer within 5 business days.   
10.3.5  Monitoring  
Designated research staff is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data reported.  All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data.  Adequate case histories of study subjects, including accurate case report forms (CRFs), and source documentation will be maintained. Data collection and accurate documentation are the responsibility of the study staff under the supervision of the investigator.  All source documents and laboratory reports must be reviewed by the study team and data entry staff, who will ensure that they are accurate and complete. Data entered into the database will be reviewed for completeness and accuracy on a weekly basis.  Unanticipated problems and adverse events must be reviewed by the investigator or designee.   
11. PARTICIPANT RIGHTS AND CO NFIDENTIALITY  
11.1 Institutional Review Board (IRB) Review   
This protocol and the informed consent document (Appendix II) will be reviewed and approved by the UMB IRB, who is responsible for oversight of the study. Any subsequent modifications to the protocol will first be reviewed by NCCIH for 
approval prior to sending them to the UMB IRB for their approval.  
Protocol Template, Version 6 38 of 54 11.2 Informed Consent Forms  
Research assistants obtaining informed consent will be experienced clinicians. 
They will receive  detailed and standardized training as to how to obtain informed 
consent from people with serious mental illnesses. They will be observed obtaining informed consent from a study participant by senior staff prior to being allowed to enroll participants on t heir own.  
 The consent form will include an explanation of the risks and benefits of participation; assurances of confidentiality; and an explanation that participation is entirely voluntary, the decision to participate will in no way influence or restrict  the 
participants access to clinical services and care at participating sites, and the participant is free to withdraw at any time with no negative consequences. As some potential participants will have poor reading skills, the consent form will be read aloud to all participants in tandem with their own silent reading of the document. 
The individual securing consent will review any points about which the participant is unclear, and the participant will be invited to ask questions as needed.  
 
11.3 Participan t Confidentiality   
All research activities will occur in a private room, behind a closed door. Careful 
procedures will be used to protect the privacy of participants and the confidentiality 
of the data. Names will only appear on consent forms and on a mast er list that links 
them with study ID numbers (different from medical record numbers). This list will 
be stored in locked files in a separate location from the data. At the conclusion of 
the project, the list will be destroyed, unless continuation is plann ed and approved 
by the Institutional Review Board. All data (whether on forms or electronic data 
files) will be collected, analyzed, and reported according to the study ID number 
and will contain no names or other personal identifiers. Paper -based data will be 
stored in locked files. Electronic data files reside on desktop computers and are 
password protected.  
11.4 Study Discontinuation  
The study may be discontinued at any time by the IRB, the NCCIH, the OHRP, the 
FDA, or other government agencies as part of their duties to ensure that research participants are protected.  
12. COMMITTEES  
N/A 
13. PUBLICATION OF RESEARCH FINDINGS  
Any presentation, abstract, or manuscript will be made available for review by the sponsor and the NCCIH prior to submission.  
14. REFERENCES  
Abrams SA, Griffin IJ, Hawthorne KM, Liang L, Gunn SK, Darlington G, Ellis KJ.  A 
Protocol Template, Version 6  39 of 54 combination of prebiotic short - and long- chain inulin -type fructans enhances calcium 
absorption and bone mineralizatin in young adolescents.  Am J Clin Nutr 82:471- 476, 2005.  
PMID: 16087995  
 
Abubucker S, et al.  Metabolic reconstruction for metagenomic data and its application to the human microbiome.  PLoS Comput Biol 8:e1002358, 2012.  PMCID  :PMC3374609  
 Addington D, Addington J, Schissel B.  A depression rating scale for schizophrenics.  Schizophr Res 3:247- 251, 1990.  PMID:2278986  
 Andreasen NC.  Negative symptom s in schizophrenia. Definition and reliability.  Arch Gen 
Psychiatry 39:784 -788, 1982.  PMID: 7165477 
 American Psychiatric Association.  Diagnostic and statistical manual of mental disorders.  5
th 
ed. Arlington: VA:  American Psychiatric Publishing, 2013.  
 Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, et al.  Enterotypes of the human gut microbiome.  Nature 473(7346):174- 180, 2011.  
PMCID:PMC3728647  
 Barta Z, Csίpõ I, Szabó GG, Szegedi G.  Seroreactivity against Saccharmo yces cerevisiae in 
patients with Crohn’s disease and celiac disease.  World J Gastroenterol 9(10):2308- 2312, 
2003.  PMCID:PMC4656483  
 Brahe LK, Astrup A, Larsen LH.  Is butyrate the link between diet, intestinal microbiota and obesity -related metabolic dis eases?  Obes Rev 14(12):950- 959, 2013.  PMID:23947604  
 Buchanan RW, Freedman R, Javitt DC, Abi -Dargham A, Lieberman JA.  Recent advances in 
the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia.  Schizophrenia Bulletin 33(5):1120- 1130, 2007.  PMCID: PMC2632365  
 Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco- Levy 
U, Carpenter WT.  The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The efficacy of glutatmatergic agents for negative symptoms and cognitive impairments.  Am J Psychiatry 164(10):1593- 1602, 2007.  PMID:17898352  
 
Caporaso JG, Juczynski J, Stombauch J, Bittinger K, Bushman FD, Costello EK, Fierer  N, et 
al.  QIIME allows analysis of high -throughput community sequencing data.  Nat Methods 
7(5):335- 336, 2010.  PMCID:PMC3156573  
 Caprihan A, Jones T, Chen H, Lemke N, Abbott C, Qualls C, Canive J, Gasparovic  C. Bustillo 
Jr.  The paradoxical relationship between white matter, psychopathology and cognition in 
schizophrenia: A diffusion tensor and proton spectroscopic imaging study.  
Neuropsychopharmacology 40(9):2248- 2257, 2015.  PMCID:4613618  
 Casellas F, Borr uel N, Torrejón, Varela E, Antolin M, Guarner F, Malagelada JR.  Oral 
oligofructose- enriched inulin supplementation in acute ulcerative colitis is well tolerated and 
associated with lowered faecal calprotectin.  Aliment Pharmacol Ther 25:1061- 1067, 2007.  
Protocol Template, Version 6  40 of 54 PMID: 17439507  
 
Chew LJ, Fusar -Poli P, Schmitz T.  Oliogdendroglial alterations and the role of microglia in 
white matter injury: Relevance to schizophrenia.  Dev Neurosci 35:102- 129, 2013.  PMCID: 
PMC4531048  
 Choi KH, Wykes T, Kurtz MM.  Adjunctive pharmacotherapy of cognitive deficits in schizophrenia: Meta- analytical investigation of efficacy.  Br J Psychiatry 203(3):172- 178, 
2013.  PMCID:PMC3759029  
 Costello EK, et al.  Bacterial community variation in human body habitats across space and time.  Science  326(5960):1694- 1697, 2009.  PMCID:PMC3602444  
 Dehghan P, Pourghassem Gargari B, Asghari Jafar -abadi M.  Oligofructose- enriched inulin 
improves some inflammatory markers and metabolic endotoxemia in women with type 2 diabetes mellitus: A randomized control led clinical trial.  Nutrition 30:418- 423, 2014.  PMID: 
24332524  
 De Peter V, Raemen H, Cloetens L, Houben E, Rutgeerts P, Verbeke K.  Effect of dietary intervention with different pre-  and probiotics on intestinal bacterial enzyme activities.  Eur J 
Clin Nutr 62:225- 231, 2008.  PMID: 17327863 
 Diaz Heijtz R, Wang S, Anuar F, Qian Y, Björkholm B, Samuelsson A, Hibberd ML, Forssberg H, Pettersson S.  Normal gut microbiota modulates brain development and behavior.  Proc Natl Acad Sci USA 108(7):3047- 3052, 2011.  PMCID:PMC3041077  
 Dinan TG, Borre YE, Cryan JF.  Genomics of schizophrenia: time to consider the gut microbiome?  Mol Psychiatry 19:1252- 1257, 2014.  PMID:25288135 
 Dixon LB, Dickerson F, Bellack AS, Bennett M, Dickinson D, Goldberg RW, Lehman A, Tenhula WN, Calmes C, Pasillas RM, Peer J, Kreyenbuhl J, Schizophrenia Patient Outcomes Research Team (PORT).  The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements.  Schizophr Bull 36(1):48- 70, 2010.  
PMCID:PMC2800143  
 Dougl as-Escobar M, Elliott E, Neu J.  Effect of intestinal microbial ecology on the developing 
brain.  JAMA Pediatr 167(4):374- 379, 2013.  PMID  :23400224  
 Dwork AJ, Mancevski B, Rosoklija G.  White matter and cognitive function in schizophrenia.  Int J Neuropsy chopharmacol 10:513- 536, 2007.  PMID:17313699  
 
Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R.  UCHIME improves sensitivity and 
speed of chimera detection.  Bioinformatics 27:2194- 2200, 2011.  PMCID:PMC3150044  
 
Eloe-Fadrosh EA, Brady A, Crabtree J, Drabek EF, Ma B, Mahurkar A, Ravel J, Haverkamp 
M, Fiorino  A -M, Botelho C, Andreyeva I, Hibberd PL, Fraser CM.  Functional dynamics of the 
gut microbiome in  elderly people during probiotic consumption.  MBio 6(2). pii: e00231- 15, 
2015.  PMCID :PMC4453556 
Protocol Template, Version 6  41 of 54  
Fadrosh DW, Ma B, Gajer P, Sengamalay N, Ott S, Brotman RM, Ravel J.  An improved dual-indexing approach for multiplexed 16S rRNA gene sequencing on the llumina MiSeq 
platform.  Microbiome 2(1):6, 2014.  PMCID:PMC3940169  
 First MB, Williams JB W, Karg RS, Spitzer RL.  Structured Clinical Interview for DSM -5—
Research Version (SCID -5 for DSM -5, Research Version; SCID -5-RV).  Arlington, VA: 
American Psychiatric Association, 2015.  
 Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, Al lensworth D, 
Guzman- Bonilla A, Clement B, Ball MP, Kutnick J, Pender V, Martin LF, Stevens KE, Wagner 
BD, Zerbe GO, Soti F, Kem WR.  Initial phase 2 trial of a nicotinic agonist in schizophrenia.  American Journal of Psychiatry 165(8):1040- 1047, 2008.  PMC ID: PMC3746983  
 Gajer P, et al.  Temporal  dynamics of the human vaginal microbiota.  Sci Transl Med 
4(132):132ra52, 2012.  PMCID:PMC3722878  
 Green MF.  What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153:321- 330, 1996.  PMID:8610818  
 Green MF, Kern RS, Heaton RK.  Logitudinal studies of cognition and functional outcome in schizophrenia: Implications for MATRICS.  Schizophr Res 72:41- 51, 2004.  PMID:15531406 
 Guy W, ed.  ECDEU Assessment Manu al for Psychopharmacology, National Institute of 
Mental Health, Rockville, MD, 1976, pp. 158- 169. 
 Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: The role of butyrate on colonic function. Aliment Pharmacol Ther 27:104- 119, 2008.  
PMID:17973645  
 The Human Microbiome Consortium.  Structure, function, and diversity of the healthy human micorbiome.  Nature 486(7402):207- 214, 2012.  PMCID:PMC3564958  
 Irvine EJ, Marshall JK. Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk. Gastroenterology 119:1740, 2000.  PMID:11113095  
 Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, et al.  The MATRICS Consensus Cognitive Battery, Part 2: Co- norming and standardization.  Am J Psychiatry 
165:214- 220, 2008.  PMID:18172018  
 Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al.  Neurocognitive 
effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial.  
Arch Gen Psychi atry 64:633- 647, 2007.    PMID:17548746  
 
Langille MG, et al.  Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences.  Nat Biotechnol 31:814- 821, 2013.  PMCID:PMC3819121  
 Lieberman JA, Dunbar G, Segreti AC, Girgis RR, Seoane F, Beaver JS, Duan N, Hosford DA.  
Protocol Template, Version 6 42 of 54 A randomized exploratory trial of an α -7 nicotinic receptor agonist (TC -5619) for cognitive 
enhancement in schizophrenia.  Neuropsychopharmacology 38(6):968- 975, 2013.   
PMCID:PMC3629385  
 
Louis P, Young P, Holtrop G, Flint HJ.  Diversity of human colonic butyrate- producing 
bacteria revealed by analysis of the butyryl -CoA:acetate CoA -transferase gene.  Environ 
Microbiol 12(2):304- 314, 2010.  PMID:19807780  
 Makharia GK, Sachdev V, Gupta R, Lal S, Anti -Saccharomyces cerevisiae antibody does not 
differentiate between Chron’s disease and intestinal tuberculosis. Dig Dis Sci 52:33- 39, 2007.  
PMID:17160471  
 Masella AP, Bartram AK, Truszkowski JM, Brown DG, Neufeld JD.  PANDAseq:  Paired -end 
asembler for illumina sequences.  BMC Bioinformatics 13:31, 2012.  PMCID:PMC3471323  
 
Najjar S and Pearlman DM.  Neuroinflammation and white matter pathology in 
schizophrenia : Systematic review.  Schizophr Res 161 :102- 112, 2015.  PMID:24948485  
 Nemani K, Hosseini Ghomi R, McCormick B, Fan X.  Schizophrenia and the gut -brain axis.  
Prog NeuropsychopharmacolBiol Psychiatry 56:155- 160, 2015.  PMID:25240858  
 Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton PK.  Identification of 
separable cognitive factors in schizophrenia.  Schizophr Res 72:29- 39, 2004.  
PMID:15531405  
 Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Coehn JD, et al.  The MATRICS Consensus Cognitive Battery, Part 1: Test selection, reliability, and validity.  Am J 
Psychiatry 165:203- 213, 2008.  PMID:18172019  
 O’Mahony SM, Clarke G , Borre YE, Dinan TG, Cryan JF . Serotonin, tryptophan metabolism 
and the brain- gut-microbiome axis. Behav Brain Res 277:32- 48, 2015.  PMID:25078296  
 Overall JE, Gorham DE.  The Brief Psychiatric Rating Scale.  Psychology Reports 10:799-812, 1961.  
 Parracho HM, Bingham MO, Gibson GR, McCartney AL.  Differences between the gut 
microflora of children with autistic spectrum disorders and that of healthy children.  J Med Microbiol 54(Pt 10):987- 991, 2005.  PMID:16157555  
 Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, Karlebach S, Gorie R, Russell J, Tacket CO, Brotman RM, Davis CC, Ault  K, Peralta L, Forney LJ.  Vaginal microbiome of reproductive- age women.  Proc Natl Acad Sci U S A 108 Suppl 1:4680- 4687, 
2011.  PMCID:PMC3063603  
 Roller M, Clune Y, Collins K, Rechkemmer G, Watzl B.  Consumption of prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis has minor effects on selected immune parameters in polypectomised and colon cancer patients.  Br J Nutr 97:676- 684, 2007.  PMID: 17349080  
Protocol Template, Version 6 43 of 54  
Rutgeerts P, Vermeire S. Clinical value of the detection of antibodies in the serum for diagnosis and treatment of inflammatory bowel disease. Gastroenterology 115:1006- 1009, 
1998.  PMID:97 86723  
 Schloss PD et al. Introducing mothur: Open- Source, platform -independent, community -
supported software for describing and comparing microbial communities. Appl Environ Microbiol 75:7537- 7541, 2009.  PMCID:PMC2786419  
 
Seedat S, Fritelli, Oosthuizen P,  Emsley RA, Stein DJ. Measuring anxiety  in patients with 
schizophrenia. J NervMent Dis 195: 320- 24, 2007.PMID: 17435482  
 
Segata N, et al.  Metagenomic biomarker discovery and explanation.  Genome Biol 12(6):R60, 2011.  PMCID:PMC3218848  
 Sellitto M, Bai G, Serena G, Fricke WF, Sturgeon C, Gajer P, White JR, Koenig SS, Kakamoto J, Boothe D, Gicquelais R, Kryszak D, Puppa E, Catassi C, Ravel J, Fasano A.  Proof of concept of microbiome- metabolome analysis and delayed gluten exposure on celiac 
disease autoimmunity in genetically at -risk infants.  PLoS One 7(3):333387, 2012. 
PMCID:PMC3303818  
 Severerance EG, Alaedini A, Yang S, Halling M, Gressitt KL, Stallings CR, Origonie AE, Vaughn C, Khushalani S, Leweke FM, Dickerson FB, Yolken RH. Gastrointestinal inflammation and asscociated immune activation in schizophrenia. Schiz Res 138:48- 63, 
2012.  PMCID:PMC4244845  
 
Severance EG, Yolken RH, Eaton WW.  Autoimmune diseases, gastrointestinal disorders 
and the micorbiome in schizophrenia: More than a gut feeling.  Schizophr Res 176(1): 23- 35, 
2016. PMCID:PMC4294997 
 Shen Y, Xu J, Li Z, Huang Y, Yuan Y, Wang J, Zhang M, Hu S, Liang Y. Analysis of gut microbiota diversity and auxiliary diagnosis as a biomarker in patients with schizophrenia: A cross- sectional study. SchizophrRes 2018, https://doi.org/10.1016/j.schres.2018.01.002  
 Sudo N, et al.  Postnatal microbial colonization programs the hypothalamic -pituitary -adrenal 
system for stress response in mice.  J Physiol 558:263- 275, 2004.  PMCID:PMC1664925  
 Tomova A, Husarova V, Lakatosova S, Bakos J, Vlkova B, Babinska K, Ostatnikova D.  Gastrointes tinal microbiota in children with autism in Slovakia.  PhysiolBehav 138:179- 187, 
2015.  PMID:25446201  Umbricht D, Keefe RS, Murray S, Lowe DA, Porter R, Garibaldi G, Santarelli L.  A randomized, placebo- controlled study investigating the nicotinic α7 agonist, RG3487, for 
cognitive deficits in schizophrenia.  Neuropsychopharmacology 39(7):1568- 1577, 2014.  
PMCID: PMC4023143  
 Vital M, Howe AC, Tiedje JM.  Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data.  MBio 5(2):e00889, 2014.  PMCID:PMC3994512  
Protocol Template, Version 6  44 of 54  
White JR, Nagarajan N, Pop M.  Statistical methods for detecting differentially abundant features in clinical metagenomic samples.  PLoSComputBiol 5:e1000352, 2009.  PMCID:PMC2661018  
 Winterer G, Gallinat J, Brinkmeyer J, Musso F, Kornhuber J, Thuerauf N, Rujescu D, Favis R, Sun Y, Franc MA, Ouwerkerk -Mahadevan S, Janssens L. Timmers M, Streffer JR.  Allosteric 
alpha- 7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: A proof -of-
mechanism study.  Neuropharmacology 64:197- 204, 2013.  PMID: 22766391  
 Xia LC, et al.  Extended local similarity analysis (eLSA) of microbial community and other time series data with replicates.  BMC Systems Biology 5 Suppl 2, S15, 2011.  PMCID:PMC3287481  
 Yolken RH, Severance EG, Sabunc iyan  S, Gressiitt KL, Chen O, Stallings C, Origoni A, 
Katsafanas E, Schweinfurth LA, Savage CL, Banis M, Khushalani S, Dickerson FB.  Metagenomic sequencing indicates that the oropharyngeal phageome of individuals with schizophrenia differs from that of c ontrols.  Schizophr Bull 41(5):1153- 1161, 2015.  PMCID: 
PMC4535630  
 Zupancic ML, Cantarel BL, Liu Z, Drabek EF, Ryan KA, Cirimotich S, Jones C, Knight R, Walters WA, Knights D, Mongodin EF, Horenstein RB, Mitchell BD, Steinle N, Snitker S, Shuldiner AR, Fraser CM.  Analysis of the gut microbiota in the old order Amish and its relation to the metabolic syndrome.  PLoS One 7(8):e43052, 2012.  PMCID:PMC3419686  
 
 
Protocol Template, Version 6  45 of 54 15. SUPPLEMENTS/APPENDICES  
 
I. Procedures Schedule  
 
Schedule of Events  2-Week 
Evaluation 
Phase  Baseline, 
Enrollment, 
Randomization  Double -Blind Treatment Phase  
Encounter # →  P1V1 P2V1   P2V2 P2V3  
Day of Study →  Day -14 to -1 
 Day 0  
 Day1 -9 Day 10  
 Day 11  
Procedure ↓       
Informed consent and ESC  X     
Demographic Forms  X     
Smoking form  X     
SCID -Interview * X     
Medical History  and EKG**  X     
Physical Exam and 
height ** X     
Dietary Assessment  X     
CMP -14, CBC  Lipid Panel  X    X 
UA; Urine Pregnancy Test 
(females)  X    X 
BPRS   X   X 
HAM -A  X   X 
Cytokines , C-reactive 
protein   X   X 
ASCA  and AGA IgG   X   X 
Tryptophan, Kynurenine, 
KYNA and 3 -HK  X   X 
OEI Challenge   X   X 
Serum Butyrate: 
preprandial, 2 hr and 6 hr 
after OEI challenge   X   X 
OEI or Placebo (Day1 -10)   X X  
Vital Signs, including 
weight, BP and pulse  X X  X X 
SEC  X   X 
Psychotropic and Non -
psychotropic Concomitant 
Medications  X    X 
 
*SCID interview can be re- used if completed within the past 5 years, with the Drug Misuse section 
re-completed at time of visit.  
 
**Medical history, EKG, physical exam, height and other screening and baseline measures can be 
collected from the TRP admissi on assessment if completed within the past 2 months.  
 
 
II. Informed Consent Form Template  
Protocol Template, Version 6 46 of 54  
RESEARCH CONSENT FORM  
 
Protocol Title:   Prebiotic Treatment in People with Schizophrenia  
 
Study No.:    HP-00081820  
 
Principal Investigator:  Robert W. Buchanan, M.D.  
    410-402-7876 
Co-Investigator:   Deanna L. Kelly, PharmD.  
    410-402-6861 
 
• Before you agree to participate in this study, it is important that you read and understand the 
following explanation of the procedures.   
• This statement describe s the purpose, procedures, benefits, risks, discomforts, and precautions of 
the study.   
• Also described are the other procedures available to you, and your right to withdraw from the study at any time.  
• It is important for you to understand that no guarant ee or assurance can be made as to the outcome 
of your participation in this study.  
• Please ask as many questions as you like before deciding to participate and during participation in this research study.   
• Your participation in this study is voluntary. 
• If you are court-ordered for treatment, or a prisoner, your participation in this study will have no 
effect on your release date, or parole.  
 
PURPOSE OF STUDY  There will be about 30 people enrolled in this study at MPRC/Spring Grove Hospital Center.  You are 
being asked to participate in this study because you have a diagnosis of schizophrenia or schizoaffective disorder.  
 The purpose this study is to examine if gut bacteria change levels of a fatty acid called butyrate after you receive 10 days of a prebiotic nutritional supplement in a drink or placebo (sugar like powder mixed in a drink); a prebiotic nutritional supplement is a natural plant fiber that beneficially nourishes the good bacteria already in the large bowel or colon.    Thirty patients at Spr ing Grove Hospital Center (SGHC) will be enrolled in this study; the study is 
being conducted by researchers from the Maryland Psychiatric Research Center (MPRC).  You are being asked to participate in this study because you have a diagnosis of schizophrenia or 
schizoaffective disorder, and therefore, may have changes in the bacteria that normally live in your 
intestine.  These changes might worsen, or even cause the symptoms of schizophrenia or schizoaffective disorder.  The bacteria in your intestines normally produce a small compound called butyrate, which is important for maintaining the healthy functioning of our intestines, and which seems 
Protocol Template, Version 6 47 of 54 to positively regulate our immune system, which fights infections and keeps us healthy.  People with 
schizophrenia and schizoaffective disorder have been found to have reduced levels of butyrate, possibly leading to unhealthy intestines, an over-active immune system, and impaired brain functioning.  Prebiotin is a natural plant fiber and nutritional supplement that is known to feed the healthy bacteria in our intestines that produce butyrate.  By taking prebiotin, we might increase the production of butyrate in our intestines, and thereby improve the health of our intestines, our immune system, and our brain.  The purpose of this study is to see if taking prebiotin for 10 days leads to an increase in butyrate in your blood.  PROCEDURES  
 
Overview:  
• If you agree to participate you will be enrolled in the study for about 3 and one-half weeks.  This will include up to 2 weeks of an evaluation phase, when information is collected to make sure you are eligible to proceed in the study.  IF you meet the study requirements, then you will proceed to a 10-day treatment phase.  
• You will have your blood work drawn at the beginning and the end of the study.  The total amount of blood drawn over the course of the study is approximately 10 tablespoons. 
• You will collect stool samples at the beginning and the end of the study 
• During the treatment phase, you will take either prebiotin or matching placebo 3 times a day for 10 days AND all participants will receive a prebiotin dose at the beginning and the end of the study.
 
• Neither you nor your doctor will know whether you are taking prebiotin or placebo  for the 10 days 
in between the two doses. 
 
Description of Evaluation Phase Visit(s): At the first evaluation phase visit, we will perform a standard 
medical workup including a physical exam, and EKG.  We will collect blood for the following laboratory measures: CBC, Chemistry Panel, liver enzymes, and lipid panel.  The total blood drawn is about three tablespoons (about 45 ml).  A urine sample will be collected for urinalysis and urine pregnancy test (if female).  We will ask you questions about your medical, psychiatric, and smoking history.  In addition, you will be shown how to collect stool samples.  This visit will take about 3 to 4 hours and may be done over two or more days. 
 
Description of the Treatment Phase Visits: If you meet inclusion criteria, you will be randomized to 
receive either the prebiotic nutri tional supplement or placebo.  Randomization is like the flip of a coin 
(a "50 -50 chance") to determine whether you will be given the prebiotic or placebo. You will be given 
the prebiotic nutritional supplement, 3 times a day, with each of your meals, for 10 days.  Your weight, height and vital signs (i.e., heart rate, pulse, and blood pressure) will be assessed at the beginning and end of the 10 days.  You will also have approximately 2 stool samples collected at the beginning and end of the 10 days.   
 In order to evaluate the impact of the prebiotic treatment on butyrate levels, we will test the ability of 
your gut bacteria to produce butyrate before and after treatment. There will be two test days: a) prior to treatment with prebiotic or placebo; and b) following the 10 day course of prebiotic or placebo treatment.  On the night prior to the test day, you will receive a completely digestible and low fiber, e.g. lasagna.  You will then fast from midnight until the morning, when you will receive your standard breakfast and a 12 gram dose of the prebiotic.  Prior to your meal, w e will collect blood for the 
following laboratory assessments: blood markers of inflammation, intestinal lining leakiness, and butyrate.  Two and 6 hours after your meal, we will collect blood samples for butyrate.  You will 
Protocol Template, Version 6 48 of 54 receive a light, low fiber meal 4 hours after you receive the prebiotin. ALL participants will receive the 
prebiotin dosing at baseline and endpoint.  
We will repeat the same procedures after you complete the 10 day course of either the prebiotic or 
placebo. If any  of these measures come back positive, then we will refer you for medical follow -up 
with the appropriate specialist, even if your participation in the study has ended. Any follow-up 
treatment with a specialist will not be part of the research study and you or your insurer will be 
responsible for any costs related to treatment. Please initial yes or no if you agree or do not agree to be contacted  about follow-up treatment after your study participation has ended.     
Yes________    No_________  At the beginning of each test day, we will ask you questions about your symptoms.  The total blood drawn for each test day is about five tablespoons (about or 75 ml.).  At day 11, you will have a urine sample collected for analysis and if you are female, you will also have a urine pregnancy test completed.  The total time for each test day visit will be about 7 hours.  WHAT ARE MY RESPONSIBILITIES IF I TAKE PART IN THIS RESEARCH?  
 If you take part in this research, you will be expected to: attend study visits as scheduled, consume the prebiotic or placebo as scheduled, follow protocol diet, allow for the drawing of blood samples, cooperate with obtaining stool samples, and take part in the study assessments.   
POTENTIAL RISKS/DISCOMFORTS:  
 
The major  risks of this study are the risk for embarrassment from the collection of stool samples.  You 
may have discomfort and bruising from the blood draw.  You may find the symptom ratings and tests stressful, and possibly frustrating, boring, or upsetting.  You may experience some embarrassment discussing personal information during interviews.  You may ask to take a break at any time.  We are protecting y our personal information but the re is still a s mall risk t hat your research records 
would be viewed by someone not authorized to see it.  To minimize this risk of someone being able to access your perso nal infor mation, your res earch recor ds will be kept in  a secure location.  
The prebiotic supplement is not absorbed into the body, but may cause gas or stomach discomfort in some people. 
POTENTIAL BENEFITS  
 
By providing blood and stool samples as part of the study, you may learn of abnormal results and be 
referred for treatment for conditions which would have otherwise gone undetected or evaluated.  There 
is also the possibility that there will be no direct benefit from participating in the study , however the 
following clinical and research -related benefits may  occur:  
1) Potential clinical benefits  for participation in the trial that are not present independent of study 
participation: 
a) You will have additional meetings with clinical and research staff for psychiatric 
symptoms and information and evaluation of study participation  
b) You will have access to life skills, illness education group, cognitive behavioral 
therapy and if a woman, women’s trauma group during your stay 
Protocol Template, Version 6 49 of 54 c) You have the opportunity to spend Day 0 and Day 11 in the research suite. This 
provides access to private lounge, videogaming, quiet space and private time 
d) You will receive counseling on diet and can participate in healthy cooking groups 
 
2) Potential research -related benefits  for participation in the trial that are not present independent 
of study participation 
a) You will have extra visits for clinical symptom ratings. These include assessment of 
positive and negative psychiatric symptoms and assessments for anxiety symptoms. 
These are not routinely completed. The doctors will receive your full results of the 
symptom ratings and may help your doctor plan better treatment 
b) You will receive standard study assessments that are above and beyond routine care. 
These include EKG, additional vital signs and bloodwork 
c) You will be monitored daily for diet and food intake and the clinical staff will have 
access to full accountability of food intake for better and more personalized 
treatment planning  
d) You will have blood drawn for inflammatory markers (cytokines) and markers for 
the gut permeability. These are not routine laboratory measures. These results will 
help clinicians know if inflammation may play a role in your illness and if 
additional treatment strategies could potentially help their psychiatric symptoms.  
e) You will have a detailed medical history completed and have daily observation. You 
will receive referrals for advanced care if needed from any clinical or research 
findings. 
f) You will learn about prebiotin and will receive information about how to get this 
treatment if they wish to continue outside of the study. 
g) You will have assessments for adverse effects. This will include a private interview 
and asking of 25 adverse effects. These may or may not be study related but allows 
for you to discuss all issues you may be having and adverse effects that you are 
dealing with. This information will help your doctor better address your problems 
which may not have been addressed previously. This may include constipation, 
indigestion, enuresis, etc. 
 
Additionally, researchers may increase their understanding of whether, and how the activity of bacteria in the intestines affects the symptoms of  schizophrenia. Your bowel movements may be more regular 
while taking the prebiotic nutritional supplement. This benefit could occur in either group as both will receive prebiotin at some point in the study.    ALTERNATIVES TO PARTICIPATION  You may choose not to participate in this study.  If you choose not participate in this study, your treatment at any facility or clinic including MPRC and Spring Grove Hospital will not be affected.   
You will be informed in a timely manner of any new findings which may affect your willingness to 
participate in this study.  
COSTS TO PARTICIPANTS  
It will not cost you anything to take part in this study. 
Protocol Template, Version 6 50 of 54 PAYMENT TO PARTICIPANTS  
You will receive $75 for completion of the evaluation phase visits and $50 for completion of the 
double-blind study visits.  The total payment for study completion is $125.    You will be paid by cash or check.  If paid by cash, then you will be pai d at th e end of each visit.  If 
paid by check, then it may take up to 4- 6 weeks to receive payment.  
CONFIDENTIALITY AND ACCESS TO RECORDS  
 All forms with information about you will have only a code number and your initials, not your full name.  With some exceptio ns, information that identifies you will not be given to people who are not 
working on this study, unless you give permission.  When you sign this consent form, you are letting us use your screening data (the information you provided when being screened for this study).  Your signature also allows us to use the data that we collect during the study itself. We also ask for approval to contact you again in the future about this study, or other studies you may qualify for.  Please initial yes or no if you agree or do not agree to be contacted.     
Yes________    No_________  The data from the study may be published. However, you will not be identified by name. People designated from the institutions where the study is being conducted auditors may be allowed to inspect sections of your medical and research records related to the study.  Everyone using study information will work to keep your personal information confidential.     Efforts will be made to reveal your personal information, including research and medical records, only to people who have a need to review this information. We cannot promise complete secrecy. Organizations that may inspect and copy your information include the IRB and other representatives of this organization.  The monitors, auditors, and the IRB will be granted direct access to your medical records for verification of the research procedures and date. By signing this document, you are authorizing this access.    
A description of this clinical trial will be available on http://www.Clinic alTrials.gov, as required by 
U.S. Law. This Web site will not include information that can identify you. At most, the Web site will 
include a summary of the results. You can search this Web site at any time. 
 
RIGHT TO WITHDRAW  
 
Your participation in this study is voluntary. You do not have to take part in this research.   You are free to withdraw your consent at anytime.  Refusal to take part or to stop taking part in the study will involve no penalty or loss of benefits to which you are otherwise entitled and will not adversely affect your treatment at MPRC, University of Maryland or Spring Grove Hospital.  If you decide to stop taking part, if you have questions, concerns, or complaints, or if you need to report a medical injury related to the research, please contact the principal investigator, Robert W. Buchanan at 410-402-7876.   
Protocol Template, Version 6  51 of 54 There are no adverse consequences (physical, social, economic, legal, or psychological) of your 
decision to withdraw from the research.  If you wish to no longer participate in the study, please notify a member of the research team. The results from the research will not provide information on your health. You will not receive any individual results.  
If you withdraw from this study, already collected data may not be removed from the study database.  
 
CAN I BE REMOVED FROM THE RESEARCH?  
 
The person in charge of the research study, the medically responsible physicians or the agencies that monitor the study can remove you from the research study without your approval. Possible reasons for removal include failure to follow instructions of the  research staff, if the person in charge decides that 
the research study is no longer in your best interest, or you are unwilling or unable to comply with the research schedule.  The study doctor will tell you about this and you will have the chance to ask questions if this were to happen.  
UNIVERSITY STATEMENT CONCERNING RESEARCH RISKS  
 The University of Maryland, Baltimore (UMB) is committed to providing participants in its research the rights due them under State and federal law. You give up none of your  legal rights by signing this consent 
form or by participating in the research project. This research has been reviewed and approved by the Institutional Review Board (IRB). Please call the Institutional Review Board (IRB) if you have questions about your rights as a research subject.  
 Participating in research may result in an injury, as explained above. If you suffer an injury directly 
related to your participation in this project, UMB and/or one of its affiliated institutions or health care groups will help you obtain medical treatment for the specific injury and provide referrals to other health care facilities, as appropriate. UMB and/or its affiliated institutions or health care groups will not provide you with financial compensation or reimburse ment for the cost of care provided to treat a 
research -related injury or for other expenses arising from a research -related injury. The institution or 
group providing medical treatment will charge your insurance carrier, you, or any other party responsible  for your treatment costs. If  you incur uninsured medical costs, they are your responsibility. 
The study staff can give you more information about this if you have a study injury.  By signing this Consent Form, you are not giving up any legal rights. If this research project is conducted in a negligent manner and you are injured as a direct result, you may be able to recover the costs of care and other damages from the individuals or organizations responsible for your injury.  
 If you have questions, concern s, complaints, or believe you have been harmed through participation in 
this research study as a result of researcher negligence, you can contact members of the IRB or the Human Research Protections Office (HRPO) to ask questions, discuss problems or conce rns, obtain 
information, or offer input about your rights as a research participant. The contact information for the IRB and the HRPO is:  
 
University of Maryland Baltimore  
Human Research Protections Office  
Protocol Template, Version 6  52 of 54 620 W. Lexington Street, Second Floor  
Baltimore, MD 21201 
410-706-5037  
 
Signing this consent form indicates that you have read this consent form (or have had it read to you), 
that your questions have been answered to your satisfaction, and that you voluntarily agree to 
participate in this research study. You will receive a copy of this signed consent form.  
 If you agree to participate in this study, please sign your name below.  
 
 
 
 ________________________________ Participant’s Signature  
  
Date:___________________________   
 ________________________________ Designee Obtaining Consent Signature  
  
Date:___________________________  
  
 
 
 _______________________________ Investigator  
   Date:___________________________  
 _______________________________ Witness  
   Date:___________________________ 
 
 
Protocol Template, Version 6 53 of 54 III. Data Safety Monitoring Board ( DSMB ) Roster  
 
MARYLAND PSYCHIATRIC RESEARCH CENTER  
DSMB BOARD MEMBERS  
 
Chair : 
 
SAaronson@sheppardpratt.org   
Scott Aaronson, M.D. is the Director of Clinical Research Programs at Sheppard and Enoch Pratt Hospital.  
 Address:  
Scott Aaronson, M.D.  
Sheppard and Enoch Pratt Hospital  
6501 North Charles Street  
Towson, MD 21285  
Work Phone: (410) 938- 3000  
 
Board Members : 
 
BobMcMahon666@gmail.com   
External Biostatistician  
Robert McMahon, Ph.D.  
 Address: 126 Rosewood Drive  
Greenbelt, MD 20770  
Phone: 443- 427-2451  
 
Glendaj6@cs.com
  
Dr. Glenda Housel is a community -practicing psychiatrist in Maryland.  
 Address:  
Glenda Housel, M.D.  
2 Esther Ann Way  
Reisterstown, MD 21136  
  
CRICHARD@som.umaryland.edu
  
Charles Richardson, M.D. is a Spring Grove Hospital psychiatrist who is in charge of the Inpatient Treatment Program  
 Address:  
Charles Richardson, M.D.  
Spring Grove Hospital Center, Tawes Bldg.  
Treatment Research Program (TRP)  
Baltimore, MD 21228  
Work Phone: 410- 402-6871  
Protocol Template, Version 6 54 of 54 Jkreyenb@som.umaryland.edu   
Julie.Kreyenbuhl@va.gov   
Julie Kreyenbuhl, Pharm.D., Ph.D. is a pharmacologist and currently a UMB, IRB Board 
Member as well. She is the Associate Director, Research Core of the VA VISM 5 MIRECC  
 Address:  
Julie Kreyenbuhl, Pharm.D., Ph.D.  
Associate Professor  
Department of Psychiatry , Division of Services Res earch  
University of Maryland School of Medicine  
Baltimore VAMC  
10 North Greene Street, Suite 6A  
(BT-MIRECC)  
Baltimore, MD 21201  
Office Phone: 410- 637,1864; Secondary Phone: 410- 706-3211  
Office Fax: 410 -637-1880  
 CLBrown@som.umaryland.edu
 
Clayton H. Brown, Ph.D. is an Associate Professor in the Department of Epidemiology, UMB School of Medicine. Dr. Brown is also the Director of the Biostatistics Core for the V.A. Capitol Healthcare Network MIRECC   Address:  
Clayton H. Brown, Ph.D.  
Associate Professor  
Department of Epidemiology and Preventive Medicine,  
University of Maryland School of Medicine  
660 West Redwood Street  
Howard Hall, Room 112  
Baltimore, Maryland 21201  
410-706-1058  
fax 410- 706-3808  
 
 
 